

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

COVID-19 Antibody in Thai Community Hospitals

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046676
Article Type:	Original research
Date Submitted by the Author:	05-Nov-2020
Complete List of Authors:	Nopsopon, Tanawin; Chulalongkorn University Faculty of Medicine Pongpirul, Krit; Chulalongkorn University Faculty of Medicine; Johns Hopkins University Bloomberg School of Public Health Chotirosniramit, Korn; Chulalongkorn University Faculty of Medicine Hiransuthikul, Narin; Chulalongkorn University Faculty of Medicine
Keywords:	Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, COVID-19

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

COVID-19 Antibody in Thai Community Hospitals

Tanawin Nopsopon¹, Krit Pongpirul^{1,2,3}, Korn Chotirosniramit¹, Narin Hiransuthikul¹

¹Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

²Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

³Bumrungrad International Hospital, Bangkok, Thailand

Correspondence to

Assist. Prof. Dr. Krit Pongpirul, MD, MPH, PhD

Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; doctorkrit@gmail.com

Words: 3,322 words (Text), 226 words (Abstract), 4 tables, 1 figure, 2 supplementary tables

ABSTRACT

Objectives: We aimed to explore the seroprevalence of hospital staffs comparing to preprocedural patients in Thai community hospitals to shed light on the situation of COVID-19 infection of frontline healthcare workers in low infection rate countries where mass screening was not readily available.

Design: Cross-sectional study.

Setting: 52 community hospitals in 35 provinces covered all region of Thailand

Participants: 857 participants consisted of 675 hospital staff and 182 pre-procedural patients

Outcome measure: COVID-19 seroprevalence using a locally developed rapid IgM/IgG test kit

Results: Overall, 5.5% of the participants (47 of 857) had positive immunoglobulin M (IgM), 0.2% (2 of 857) had positive immunoglobulin G (IgG) which both of them also had positive IgM. Hospitals located in the central part of Thailand had the highest IgM seroprevalence (11.9%). Preprocedural patients had a higher rate of positive IgM than the hospital staff (12.1% vs. 3.7%). Participants with present upper respiratory tract symptoms had a higher rate of positive IgM than those without (9.6% vs. 4.5%). Three quarters (80.5%, 690 of 857) of the participants were asymptomatic, of which, 31 had positive IgM (4.5%) which consisted of 20 of 566 healthcare workers (3.5%) and 11 of 124 preprocedural patients (8.9%).

Conclusions: COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals. Antibody testing should be encouraged for mass screening, especially in asymptomatic individuals.

Trial registration: Thai Clinical Trials Registry: TCTR20200426002

MeSH Keywords: COVID-19, severe acute respiratory syndrome coronavirus 2, Seroepidemiologic Studies, Hospitals, Thailand

Strengths and limitations of this study

- ▶ This study covered all regions in Thailand and consisted of community hospitals from 35 out of 77 provinces.
- ▶ We used a locally developed IgM/IgG test kit with high internal validation to shed light on the actual COVID-19 situation in an area in which PCR testing was not readily available.
- ▶ This study provided a real-life experience to gather crucial information despite limited and restricted resources.
- ▶ We did not have a chance to perform the serological test among the COVID-19 confirmed cases as the mild case had to get quarantined and the moderate and severe ones were referred to a higher level of care, which could affect the seroprevalence.
- ▶ We could not perform multiple serological tests at different time points as doing so was not approved by the ethics committee.

INTRODUCTION

Polymerase chain reaction (PCR) was introduced as a diagnostic test of choice for coronavirus disease 2019 (COVID-19) infection. However, it might not be readily available or affordable in many facilities and could pose an unnecessary risk to the healthcare providers during the specimen collection. Besides, a recent study raised a concern of false-negative results from the PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with high pretest probability and encouraged the development of a highly sensitive test.¹ In Thailand, the PCR test was offered in suspected individuals with strict criteria during the initial phase of the COVID-19 pandemic. As a more feasible, cheaper, and safer alternative to the PCR, the antibody test is not only useful for an epidemiological investigation but could also be used for mass screening of potential silent spreaders—asymptomatic COVID-19 individuals.²

Hospital is one of the best venues for getting and spreading pathogens. There are two types of people in the hospital who potentially are silent spreaders and need antibody testing: (1) healthcare workers who have a relatively higher risk of infection than laypersons, and (2) asymptomatic patients who need procedural treatment or operation but do not meet the criteria for PCR testing.

METHODS

Study Population

From 8th April to 26th June 2020, hospital staff and patients who needed procedural treatment or operation visiting the hospital during the recruiting period and did not meet the national PCR testing criteria in 244 hospitals (215 community hospitals and 29 general hospitals) from all regions of Thailand were recruited for antibody testing in their community hospital. Hospitals included in the study came from a national survey about willingness to use antibody testing for COVID-19 screening. Of 215 community hospitals, data from 52 hospitals (24.2%) in 35 provinces from all regions which could be considered representative of community hospitals across Thailand were readily available for the analysis performed on June 29, 2020. Participants with active symptoms meeting national criteria for PCR testing were quarantined and excluded. Participants were asked to answer a questionnaire about risk history for COVID-19, recent symptoms within the past two weeks, and previous PCR test results if available.

National criteria for PCR testing for COVID-19

1
2
3 National criteria for PCR testing for COVID-19 for symptomatic layperson during the study period included fever
4 with one of the upper respiratory infection symptoms (cough, rhinitis, sore throat, anosmia, tachypnea, or dyspnea)
5 and one of risk history (history of travel to a high-risk area, an occupation involving tourists, crowded place, or
6 contact with many people, history of going to crowded place in the community, or history of close contact
7 confirmed COVID-19 case) within 14 days before the onset of symptoms. For symptomatic healthcare workers, the
8 criteria were less strict. Either fever or one of the upper respiratory infection symptoms was sufficient for PCR
9 testing. During the recruiting period, there was almost impossible for an asymptomatic person to get PCR tested.
10

17 **Antibody testing**

19 Baiya Rapid COVID-19 IgG/IgM test kit (Baiya Phytopharm, Thailand) which reports the presence of
20 immunoglobulin M (IgM) and immunoglobulin G (IgG) qualitatively using lateral flow immunoassay technique and
21 receptor-binding protein of spike protein of SARS-CoV-2 for antigen, was used in this study free of charge. The
22 internal validation of the test kit using the serum of 51 PCR confirmed COVID-19 cases and 150 controls showed
23 sensitivity 94.1% (48 of 51) and specificity 98.0% (147 of 150) for IgM or IgG antibody. Of 51 PCR confirmed
24 COVID-19 cases, 56.9% (29 of 51) were IgM+ IgG-, 37.3% (19 of 51) were IgM+ IgG+, 5.9% (3 of 51) were IgM-
25 IgG-. No IgM- IgG+ was detected in 51 PCR confirmed COVID-19 cases from interval validation. Participants with
26 positive IgM were encouraged to have a PCR test if available. There was no hospital or center readily available for
27 neutralizing antibody testing during the study period.
28
29
30
31
32
33
34
35
36

37 **Age-adjusted seroprevalence**

39 PCR confirmed COVID-19 cases were obtained from the Thailand government report on June 30, 2020.
40 Seroprevalence data were presented as unadjusted seroprevalence and compared with direct age-adjusted
41 seroprevalence using combined participating population, Thailand population, and world population provided by
42 world health organization (WHO) for 2000-2025 population.
43
44
45
46
47

48 **Statistical analysis**

50 Categorical data were presented with counts and percentages while continuous data were provided with median and
51 interquartile range. The 95% confidence interval (CI) of the seroprevalence was calculated by Wilson's method
52 using binomial probabilities. Correlation between seroprevalence and PCR confirmed COVID-19 prevalence was
53 tested using Spearman's correlation. Missing data were excluded. A two-tailed $p < 0.05$ was considered statistically
54
55
56
57

1
2
3 significant. All data were analyzed using Stata 16.1 (College Station, TX).
4

5 **Patient and public involvement statement**

6
7 The research question and outcome measure were developed from both patient and public involvement. For patient
8 involvement, visiting a hospital must not harm patients; however, the unknown status of COVID-19 infection in the
9 pandemic period led to a doubtful situation of no harm. For public involvement, the national policy about the
10 COVID-19 test at the study period made an unstable situation among the public, a national survey was conducted to
11 identify a situation in the community and general hospitals to find places that should be the priority for this study to
12 provide more confidence situation for hospital visiting and working. Patients and hospital staff who participated in
13 this study had a report for their serology status, and the results of this study would be disseminated not only to
14 participants but also to the public via an online channel to provide evidence of the actual situation.
15
16
17
18
19
20
21
22

23 **RESULTS**

24 **Community hospital demographic**

25
26 Overall, 52 community hospitals from 46.1% of provinces in Thailand (35 of 76) which consisted of 58.2% of
27 national population (35,416,545 of 60,892,671) participated in this study. Participation rates varied across regions—
28 Northeastern (55%), Central (50.0%), Southern (42.9%), Northern (33.3%), and Eastern (28.6%) (supplementary
29 table E1).
30
31
32
33
34
35


36 **Participant demographic**

37
38 From 52 community hospitals, 857 participants which consisted of 675 hospital staff and 182 pre-procedural
39 patients were included in the study. Their median age was 37 years (interquartile range 27–45), 74.7% were female,
40 98.8% were Thai, and 80.5% were asymptomatic. The most common symptoms were cough (9.7%), rhinitis (7.5%),
41 sore throat (6.4%), fever (5.7%), and dyspnea (3.5%). History of travel to the high-risk area was 6.0%, history of
42 close contact to the confirmed COVID-19 case was 15.4%, and 14.5% had PCR negative (table 1). Forty-seven
43 participants (5.5%, 95% CI 4.1 to 7.2) had IgM antibody against SARS-CoV-2 whereas the IgG antibody was found
44 in two participants (0.2%, 95% CI 0.1 to 0.8). Participants from the Central region of Thailand had the highest IgM
45 seroprevalence (11.9%, 95% CI 8.4 to 16.5), while the Northern region had the lowest seroprevalence (1.6%, 95%
46 CI 0.3 to 8.7) (figure 1).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Demographic details of participants

	All Participants N (%)	Hospital Staff n (%)	Pre-procedural Patients n (%)
Total	857	675	182
Median age, years (25th–75th percentile)	37 (27–45)	36.5 (28–45)	37 (25–53)
Male	207 (24.1%)	145 (21.5%)	62 (34.1%)
Female	640 (74.7%)	521 (77.2%)	119 (65.4%)
Unspecified	10 (1.2%)	9 (1.3%)	1 (0.5%)
Thai	847 (98.8%)	671 (99.4%)	176 (96.7%)
Non-Thai	10 (1.2%)	4 (0.6%)	6 (3.3%)
Region			
North	61 (7.1%)	59 (8.8%)	2 (1.1%)
Northeast	269 (31.4%)	220 (32.6%)	49 (26.9%)
Central	244 (28.5%)	183 (27.1%)	61 (33.5%)
South	109 (12.7%)	88 (13.0%)	21 (11.6%)
East	174 (20.3%)	125 (18.5%)	49 (26.9%)
History of travel to high-risk area			
Yes	51 (6.0%)	20 (3.0%)	31 (17.0%)
No	806 (94.0%)	655 (97.0%)	151 (83.0%)
History of close contact confirmed case			
Yes	132 (15.4%)	121 (17.9%)	11 (6.0%)
No	725 (84.6%)	554 (82.1%)	171 (94.0%)
Asymptomatic	690 (80.5%)	566 (83.9%)	124 (68.1%)
Symptomatic	167 (19.5%)	109 (16.1%)	58 (31.9%)
Fever	49 (5.7%)	17 (2.5%)	32 (17.6%)
Cough	83 (9.7%)	52 (7.7%)	31 (17.0%)
Rhinitis	64 (7.5%)	47 (7.0%)	17 (9.3%)
Sore throat	55 (6.4%)	37 (5.5%)	18 (9.9%)
Dyspnea	30 (3.5%)	3 (0.4%)	27 (14.8%)
Previous PCR status			
Negative	124 (14.5%)	77 (11.4%)	47 (25.8%)
Never tested	733 (85.5%)	598 (88.6%)	135 (74.2%)

Data were presented in counts and percentages unless otherwise specified.
PCR, polymerase chain reaction.



40
41 **Figure 1** Unadjusted IgM Seroprevalence in Community Hospitals across Geographical Regions of Thailand

42 43 **Age-adjusted immunoglobulin M (IgM) seroprevalence**

44
45 Age-adjusted IgM seroprevalence with combined participating population showed almost similar results with
46 unadjusted IgM seroprevalence. However, age-adjusted seroprevalence using Thailand population showed
47 increasing seropositive rate in Thailand from 5.5% to 6.3%, Central region from 11.9% to 15.3%, and Northern
48 region from 1.6% to 1.8%, while decreasing seroprevalence in Northeastern region from 3.0% to 1.6%, Eastern
49 region from 4.0% to 2.8%, and Southern region from 1.8% to 1.5%. Adjusted with the world standard population
50
51
52
53
54
55
56
57
58
59
60

from the World Health Organization (WHO 2000-2025) showed decreasing trends of seroprevalence both overall and in most regions (table 2).

Table 2 Unadjusted and age-adjusted immunoglobulin M seroprevalence in community hospitals across geographical regions of Thailand

Regions	Unadjusted IgM Seroprevalence	Age-adjusted IgM Seroprevalence with Combined Participating Population	Age-adjusted IgM Seroprevalence with Thailand Population	Age-adjusted IgM Seroprevalence with World Standard Population
Thailand*	5.5%	NA	6.3%	5.1%
Northern	1.6%	2.2%	1.8%	2.1%
Northeastern	3.0%	3.0%	1.6%	1.5%
Central*	11.9%	11.9%	15.3%	12.2%
Southern	1.8%	2.4%	1.5%	1.2%
Eastern	4.0%	3.9%	2.8%	2.6%

* Not include Bangkok which has no community hospital.
IgM, immunoglobulin M; NA, not available; WHO, World Health Organization.

Participant characteristics and seroprevalence

Pre-procedural patients had an unexpectedly higher proportion of positive IgM than the hospital staff (12.1% vs. 3.7%), especially patients in the Central region of Thailand (27.9%, 95% CI 18.2 to 40.2) while patients in the Northern and Southern regions showed zero seroprevalences. Also, hospital staff in the Central region had the highest seroprevalence (6.6%, 95% CI 3.8 to 11.1) while those in the Northern region had the lowest (1.7%, 95% CI 0.3 to 9.0). Overall, the seropositive prevalence was not different between males and females (5.8% vs. 5.5%). Paradoxically, the seroprevalences were higher in participants without a history of travel to a high-risk area (5.6% vs. 3.9%) and those without a history of close contact to confirmed COVID-19 case (5.7% vs. 4.5%) than their counterparts. The same paradox is also applied to pre-procedural patients. Patients without travel history were likely to have an antibody for SARS-CoV-2 (13.9% vs. 3.2%) and patients without close contact to the case also had more chance to develop an antibody (12.3% vs. 9.1%). However, healthcare workers with travel history had slightly more chance to develop IgM (5.0% vs. 3.7%) and with close contact history (4.1% vs. 3.6%). In general, participants with upper respiratory tract symptoms had a higher chance of being seropositive (9.6% vs. 4.5%), of which dyspnea had the highest (30.0%, 95% CI 16.7 to 47.9). Likewise, pre-procedural patients with dyspnea had the most IgM positive (29.6%, 95% CI 15.9 to 48.5), and healthcare workers with dyspnea (33.3%, 95% CI 6.1 to 79.2). Of 690

participants without present upper respiratory tract symptom, 31 had IgM positive for COVID-19 (4.5%, 95% CI 3.2 to 6.3) which consisted of 20 of 566 healthcare workers (3.5%, 95% CI 2.3 to 5.4) and 11 of 124 patients (8.9%, 95% CI 5.0 to 15.2). History of negative PCR was associated with a surprisingly higher chance of seropositive than those with no PCR test result (6.5% vs. 5.3%) (table 3). Unfortunately, none of the participants with positive IgM had opportunities for PCR testing.

Table 3 Demographic characteristics and seroprevalence in hospital staff and pre-procedural patients

	All Participants		Hospital Staff		Pre-procedural Patients	
	N	IgM+	n	IgM+	n	IgM+
Total	857	47 (5.5%)	675	25 (3.7%)	182	22 (12.1%)
Median age, years (25th–75th percentile)	37 (27–45)		36.5 (28–45)		37 (25–53)	
Male	207 (24.1%)	12 (5.8%)	145(21.5%)	6 (4.1%)	62 (34.1%)	6 (9.7%)
Female	640 (74.7%)	35 (5.5%)	521(77.2%)	19 (3.6%)	119 (65.4%)	16 (13.4%)
Unspecified	10 (1.2%)	0 (0.0%)	9 (1.3%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
Thai	847	47 (5.5%)	671	25 (3.7%)	176	22 (12.5%)
Non-Thai	10	0(0.0%)	4	0 (0.0%)	6	0 (0.0%)
Region						
North	61	1 (1.6%)	59	1 (1.7%)	2	0 (0.0%)
Northeast	269	8 (3.0%)	220	4(1.8%)	49	4 (8.2%)
Central	244	29 (11.9%)	183	12 (6.6%)	61	17 (27.9%)
South	109	2 (1.8%)	88	2 (2.3%)	21	0 (0.0%)
East	174	7 (4.0%)	125	6 (4.8%)	49	1 (2.0%)
History of travel to high risk area						
Yes	51	2 (3.9%)	20	1 (5.0%)	31	1 (3.2%)
No	806	45 (5.6%)	655	24 (3.7%)	151	21 (13.9%)
History of close contact confirmed case						
Yes	132	6(4.5%)	121	5(4.1%)	11	1 (9.1%)
No	725	41 (5.7%)	554	20 (3.6%)	171	21 (12.3%)
Asymptomatic	690	31 (4.5%)	566	20 (3.5%)	124	11 (8.9%)
Symptomatic	167	16 (9.6%)	109	5 (4.6%)	58	11 (19.0%)
Fever	49	7 (14.3%)	17	0 (0.0%)	32	7 (21.9%)
Cough	83	8 (9.6%)	52	1 (1.9%)	31	7 (22.6%)
Rhinitis	64	7 (10.9%)	47	2 (4.3%)	17	5 (29.4%)
Sore throat	55	8 (14.5%)	37	3 (8.1%)	18	5 (27.8%)
Dyspnea	30	9 (30.0%)	3	1 (33.3%)	27	8 (29.6%)
Previous PCR status						
Negative	124	8 (6.5%)	77	1 (1.3%)	47	7 (14.9%)
Never tested	733	39 (5.3%)	598	24 (4.0%)	135	15 (11.1%)

Data were presented in counts and percentages unless otherwise specified.

IgM+, immunoglobulin M positive; NA, not available; PCR, polymerase chain reaction.

COVID-19 prevalence and immunoglobulin M seroprevalence

PCR-confirmed COVID-19 case and population data were acquired for participating provinces. Overall, COVID-19 prevalence was 2.44 cases per 100,000 population. Participating provinces in the Eastern region had the highest prevalence of COVID-19 (6.54 cases per 100,000 population) while provinces in northeastern had the lowest prevalence (supplemental table E2). There was no correlation between IgM seroprevalence, and PCR confirmed COVID-19 prevalence (p=0.199).

Characteristics of immunoglobulin G seropositive participants

IgG was detected in two participants (0.2%, 95% CI 0.1 to 0.8) who also had a positive IgM antibody. In other words, we did not find any participants with isolated positive IgG. Participant A was a Thai female healthcare worker who worked in a community hospital in the Central region of Thailand. She had a sore throat but had no history of travel to a high-risk area or close contact to confirmed COVID-19 case and did not have a PCR test before. Participant B was a Thai female preprocedural patient who visited another community hospital in the Central region. She had no symptom, no history of travel to a high-risk area, or close contact to confirmed COVID-19 case. Participant B had a previously negative PCR result (table 4).

Table 4 Characteristics of Participants who Developed Immunoglobulin G Antibody

	Age Range, years	Gender	Ethnicity	Region	Occupation	History of travel to a high-risk area	History of contact to a confirmed case	Symptoms	Previous PCR status
Participant A	56-60	Female	Thai	Central	HCW	No	No	Sore throat	Never tested
Participant B	41-45	Female	Thai	Central	Patient	No	No	No	Negative

HCW, healthcare worker; PCR, polymerase chain reaction; Age range was used for participant's privacy and confidentiality.

DISCUSSION

COVID-19 seroprevalence in asymptomatic staff and patients in Thai community hospitals was higher than hospitals in China (4.5% vs. 2.5%).³ Seroprevalence in asymptomatic hospital staff in Thailand was also higher than hospitals in China (3.5% vs. 1.8%)³ but less than a tertiary hospital in Belgium (3.5% vs. 6.4%).⁴ Moreover, seroprevalence in asymptomatic hospital staff in Thailand was less than asymptomatic frontline firefighters/paramedics of the US fire department (3.5% vs 7.7%).⁵ Asymptomatic patients in Thailand seemed to have higher seroprevalence than China (8.9% vs. 3.5%).³ Unlike China and Belgium where the seroprevalences were mostly from positive IgG, our study revealed mostly positive IgM. Comparison with Belgium hospital should be interpreted with caution due to the unknown PCR status of Belgium subjects.

People with a history of travel to a high-risk area or close contact to confirmed COVID-19 case turned out to have a low COVID-19 seroprevalence in our study. One possible explanation could be the successful implementation of the national PCR-based screening policy, low barrier to medical care under the Universal Coverage scheme as well as disease awareness and health literacy of the Thais. People with those predefined risks might have already sought medical attention; several cases might have been identified with the PCR test and were

1
2
3 either quarantined or sent to proper care. The remaining eligible individuals might be dominated by those without
4 predefined risks.
5

6
7 To prevent nosocomial spread in a community hospital or primary hospital setting, hospital staff should be
8 tested for COVID-19 before working their routine and should repeat the test at a specified period. Antibody testing
9 was less uncomfortable than PCR testing which might lead to more compliance when hospital staff was planned to
10 get multiple tests. False-negative could occur in any test. High sensitivity testing was encouraged for the high-risk
11 population including hospital staff to reduce false negative.¹ Negative result on PCR with negative antibody test or
12 IgG positive only might be acceptable for hospital staff starting the work when such a highly sensitive test was not
13 completely developed. To help prevent community spread in an aspect of a community hospital setting, patients who
14 visited the hospital with any chief complain should be tested with rapid antibody testing to screen some potential
15 spreader and prevent them from returning to the community during spreadable period especially when PCR testing
16 was not readily available in a remote area.
17
18
19
20
21
22
23
24
25
26

27 Serological testing provides some crucial epidemiological information and would have been more effective
28 when combined with other diagnostic tests such as PCR. While all participants with positive results from the free-of-
29 charge rapid IgM/IgG test provided in this study were encouraged to get PCR testing, a majority of community
30 hospitals still did not have access to the PCR testing because of both financial and non-financial reasons.
31 Recommendation for PCR testing after positive rapid IgM/IgG test was not fully complied so we did not have
32 information about the participants with positive IgM. However, with the immunoglobulin status and PCR results, we
33 can shape the situation more accurately for both individual and regional views. Hopefully, with this and other
34 vigorous and dedicated studies on antibody status around the globe, serology testing would provide useful
35 information for pandemic control.
36
37
38
39
40
41
42
43
44

45 The relatively predominant positive IgM status compared to positive IgG might relate to the exclusion
46 criteria of our observational study as all confirmed COVID-19 cases were already excluded according to the national
47 protocol. Given the fact that IgM represents an acute infection while IgG is suggestive of past infection, excluding
48 COVID-19 confirmed cases who had a higher chance of developing IgG during the study period would
49 underestimate the actual IgG seroprevalence and underestimate the actual proportion of seropositive participants
50 who had previous PCR testing. While this might be considered a limitation of our study as compared to other studies
51
52
53
54
55
56
57
58
59
60

1
2
3 that did not exclude COVID-19 confirmed cases, our observation reflected a real picture of seroprevalence in a
4 country with low COVID-19 incidence and mortality. We did not have a chance to perform the serological test
5 among the COVID-19 confirmed cases as the mild case had to get quarantined and the moderate and severe ones
6 were referred to a higher level of care. Also, we could not perform multiple serological tests at different time points
7 as doing so was not approved by the ethics committee.
8
9
10
11
12

13 Only 2 out of 47 IgM positive participants also had IgG positive and none of IgM positive participants got
14 subsequent PCR test after IgM positive status. There was a possibility that IgM positive might be false positive.
15 However, the false-positive rate for IgM or IgG was 2% according to internal validation of test kit while IgM
16 positive seroprevalence was 5.5%. While the false positive of IgM might occur due to imperfection of test kit and no
17 confirmation with PCR test after positive antibody against COVID-19 which might lead to overestimation of actual
18 IgM seroprevalence, this limitation shaped the real-world situation in the early phase of pandemic awareness in a
19 community hospital setting where more advanced test methods were not readily available.
20
21
22
23
24
25
26

27 **CONCLUSIONS**

28
29 COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals.
30
31 Antibody testing should be encouraged for mass screening, especially in asymptomatic individuals.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgements** We thank Baiya Phytopharm, Thailand for supporting the Baiya Rapid COVID-19 IgG/IgM
4 test kit. The company did not involve in the data analysis, interpretation, and manuscript preparation.

5
6
7 **Contributors** TN conceptualized the study, design methodology, administrated the project, contributed to data
8 curation and clinical investigation, validate the data, performed formal analysis and provided software, visualized
9 the data, and wrote the original draft of the manuscript. KP conceptualized the study, design methodology,
10 administrated the project, contributed to data curation and clinical investigation, validate the data, performed formal
11 analysis and provided software, provided resources for the study, supervised the study, and wrote the original draft
12 of the manuscript. KC contributed to data curation and clinical investigation, and validate the data. NH
13 conceptualized the study, design methodology, administrated the project, provided resources for the study, and
14 supervised the study. All authors reviewed, edited the final manuscript, agreed to be held accountable for all aspects
15 of the work related to its accuracy and integrity.

16
17
18 **Funding** The authors have not declared a specific grant for this research from any funding agency in the public,
19 commercial, or not-for-profit sectors.

20
21
22 **Competing Interests** None declared.

23
24
25 **Patient and public involvement** Patient and/or the public were involved in the design, or conduct, or reporting, or
26 dissemination plans of this research. Refer to the Methods section for further details.

27
28
29 **Patient consent for publication** Not required.

30
31
32 **Ethics approval** Ethics approval was obtained from the Institutional Review Board of Chulalongkorn University
33 (IRB No.236/63), Ethics Committee of National Cancer Institute Thailand (EC No.015/2563), Research Ethics
34 Committee of Nan Hospital (REC No.063/2563), Ethics Committee of Chaophraya Yommarat Hospital (YM
35 No.013/2563), Institutional Review Board of Songkhla Hospital (IRB No.2020-Md-J3-04001), Ethics Committee of
36 Lampang Hospital (EC No.26/63), Ethics Committee of Sikhio Hospital (SK No.2020/001), Ethics Committee of
37 Samut Sakhon Hospital, Research Ethics Committee of Prapokklao Hospital (CTIREC No.030/63), Institutional
38 Review Board of Burapha University (HS No.027/2563), Ethics Committee of Srinakharinwirot University
39 (SWUEC No. 119/2563F), Institutional Review Board of Phaholpolpayuhasena Hospital (IRB No.2020-04),
40 Institutional Review Board of Samitivej Sukhumvit Hospital (IRB No.001/2563), Research Ethics Committee of
41 Pattani Provincial Public Health Office (RECPTN No.015/63), Institutional Review Board of Bangplee Hospital
42 (IRB No.1/2563), Institutional Review Board of Chonburi Hospital (IRB No.08/2563), Institutional Review Board
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3 of Surin Hospital (IRB No.15/2563), Institutional Review Board of Child and Adolescent Mental Health
4
5 Rajanagarindra Institute (IRB No.2563/005) and Institutional Review Board of Sukhothai Hospital (IRB
6
7 No.44/2563). Given no ethics committees available in the participating community hospitals, participation in this
8
9 study was approved by the hospital directors or representatives. All participants provided written informed consent
10
11 including consent for publication of raw data. (Thai Clinical Trials Registry: TCTR20200426002)
12

13 **Data availability statement** All data relevant to the study are included in the article; the anonymized dataset is
14
15 available upon requested by emailing doctorkrit@gmail.com
16
17

18 19 20 REFERENCES

- 21
22
23 1 Woloshin S, Patel N, Kesselheim A. False Negative Tests for SARS-CoV-2 Infection - Challenges and
24 Implications. *N Engl J Med* 2020 doi: 10.1056/NEJMp2015897 [published Online First: 2020/06/06]
25 2 Yong S, Anderson D, Wei W, et al. Connecting clusters of COVID-19: an epidemiological and
26 serological investigation. *Lancet Infect Dis* 2020 doi: 10.1016/s1473-3099(20)30273-5 [published
27 Online First: 2020/04/25]
28 3 Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2
29 in China. *Nat Med* 2020 doi: 10.1038/s41591-020-0949-6 [published Online First: 2020/06/07]
30 4 Steensels D, Oris E, Coninx L, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in
31 a Tertiary Center in Belgium. *Jama* 2020 doi: 10.1001/jama.2020.11160 [published Online First:
32 2020/06/17]
33 5 Caban-Martinez A, Schaefer-Solle N, Santiago K, et al. Epidemiology of SARS-CoV-2 antibodies
34 among firefighters/paramedics of a US fire department: a cross-sectional study. *Occup Environ Med*
35 2020 doi: 10.1136/oemed-2020-106676 [published Online First: 2020/08/06]
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



118x151mm (120 x 120 DPI)

COVID-19 Antibody in Thai Community Hospitals

SUPPLEMENTARY FILES

Supplemental Table E1 Geographical distribution of 52 participating community hospitals

	Participating Provinces	Total Provinces	Population of Participating Provinces	Population of All Provinces
Thailand*	35 (46.1%)	76	35,416,545 (58.2%)	60,892,671
Northern	3 (33.3%)	9	2,505,118 (39.4%)	6,350,499
Northeastern	11 (55.0%)	20	15,064,919 (68.4%)	22,014,248
Central*	13 (50.0%)	26	10,053,397 (55.3%)	18,192,361
Southern	6 (42.9%)	14	5,697,112 (60.0%)	9,493,757
Eastern	2 (28.6%)	7	2,095,999 (43.3%)	4,841,806

* Not include Bangkok which has no community hospital.

Data were presented in counts and percentages.

Supplemental Table E2 Number and prevalence of PCR confirmed COVID-19 cases in participating provinces

	PCR Confirmed COVID-19 Cases	Population	PCR Confirmed COVID-19 Prevalence per 100,000 Population
Overall	864	35,416,545	2.44
Northern	47	2,505,118	1.88
Chiang Mai	41	1,779,254	2.30
Mae Hong Son	5	284,138	1.76
Phrae	1	441,726	0.23
Northeastern	85	15,064,919	0.56
Buriram	13	1,595,747	0.81
Chaiyaphum	3	1,137,357	0.26
Kalasin	3	983,418	0.31
Khon Kaen	6	1,802,872	0.33
Maha Sarakham	1	962,665	0.10
Mukdahan	4	353,174	1.13
Nakhon Phanom	2	719,136	0.28
Nakhon	19	2,648,927	0.72
Ratchasima			
Surin	9	1,396,831	0.64
Ubon Ratchathani	15	1,878,146	0.80
Udon Thani	10	1,586,646	0.63
Central	383	10,053,397	3.81
Ayutthaya	4	820,188	0.49
Chainat	0	326,611	0.00
Lopburi	2	755,556	0.26
Nakhon Pathom	22	920,030	2.39
Nonthaburi	158	1,265,387	12.49
Pathum Thani	39	1,163,604	3.35
Phetchaburi	2	485,191	0.41
Phichit	0	536,311	0.00
Samut Prakan	143	1,344,875	10.63
Sukhothai	3	595,072	0.50
Suphanburi	6	846,334	0.71
Tak	3	665,620	0.45
Uthaithani	1	328,618	0.30
Southern	212	5,697,112	3.72
Chumphon	21	511,304	4.11
Krabi	20	476,739	4.20
Nakhon Si	12	1,561,927	0.77
Thammarat			
Songkhla	134	1,435,968	9.33
Surat Thani	18	1,068,010	1.69
Trang	7	643,164	1.09
Eastern	137	2,095,999	6.54
Chanthaburi	3	537,698	0.56
Chonburi	134	1,558,301	8.60

PCR, polymerase chain reaction.

	Hospital	No	Gender	Age	Travel to HiClose	conta	Healthcare	Thai	Previous	PC
1										
2	Hospital1									
3		1	0	49	0	0	1	1	0	
4		2	0	55	0	0	1	1	0	
5		3	0	53	0	0	1	1	0	
6		4	0	40	0	1	0	1	0	
7		5	1	40	0	1	1	1	0	
8		7	0	42	0	0	1	1	0	
9		8	0	44	0	0	0	1	0	
10		9	0	33	0	0	0	1	0	
11		10	0	29	0	0	0	1	0	
12		11	1	34	0	1	1	1	0	
13		12	1	30	0	0	0	1	0	
14		13	0	42	0	0	1	1	0	
15		14	0	26	0	1	1	1	0	
16		15	0	24	0	0	0	1	0	
17		16	0	24	0	0	0	1	0	
18		17	0	29	0	1	1	1	0	
19		18	0	36	0	0	1	1	0	
20		19	0	53	0	0	0	1	0	
21		20	0	48	0	0	1	1	0	
22		21	0	26	0	1	1	1	0	
23		22	0	33	0	1	1	1	0	
24	Hospital2	1	0	32	0	0	1	1	1	
25		2	0	26	0	0	1	1	1	
26		3	0	35	0	0	1	1	1	
27		4	0	45	0	0	1	1	1	
28		5	0	43	0	0	1	1	1	
29		6	0	34	0	0	1	1	0	
30		7	0	22	0	0	1	1	0	
31		8	0	36	0	0	1	1	0	
32		9	0	31	0	0	1	1	0	
33		10	0	39	0	0	1	1	0	
34		11	0	42	0	0	1	1	0	
35		12	0	40	0	0	1	1	0	
36		13	0	35	0	0	0	1	0	
37		14	0	50	0	0	1	1	0	
38		15	1	27	0	0	1	1	0	
39		16	0	31	0	0	1	1	0	
40		17	1	36	0	0	1	1	0	
41		18	0	25	0	0	1	1	0	
42		19	0	32	0	1	1	1	0	
43		20	0	26	0	0	1	1	0	
44		21	0	40	0	0	1	1	0	
45		22	0	37	0	0	1	1	0	
46		24	0	51	0	0	1	1	0	
47		25	0	47	0	0	1	1	0	
48		26	0	45	0	0	1	1	0	
49		27	1	29	0	0	1	1	0	
50		28	0	40	0	0	1	1	0	
51		29	0	34	0	0	1	1	0	
52		30	0	36	0	0	0	1	0	
53		31	0	52	0	0	1	1	0	

1									
2		32	0	28	0	0	1	1	0
3		33	1	27	0	0	1	1	0
4		34	0	30	0	0	1	1	0
5		35	0	25	0	0	1	1	0
6		36	0	41	0	0	1	1	0
7		37	0	40	0	0	1	1	0
8		38	0	47	0	0	1	1	0
9		39	0	29	0	0	1	1	0
10		40	0	37	0	0	0	1	0
11		40	0	37	0	0	0	1	0
12	Hospital3	1	1	45	0	0	1	1	0
13		2	0	26	0	0	1	1	0
14		3	0	53	0	0	1	1	0
15		4	0	26	0	0	1	1	0
16		5	0	48	0	0	1	1	0
17		6	0	44	0	0	1	1	0
18		6	0	44	0	0	1	1	0
19		7	0	44	0	0	1	1	0
20		8	0	32	0	0	1	1	0
21		9	0	31	0	0	1	1	0
22		9	0	31	0	0	1	1	0
23		10	0	41	1	0	1	1	0
24		11	0	38	0	0	1	1	0
25		12	0	32	0	0	1	1	0
26		13			0	0	1	1	0
27		14	0	25	0	0	1	1	0
28		15	0	45	0	0	1	1	0
29		16	0	31	0	0	1	1	0
30		17	1	20	0	0	1	1	0
31		18	0	46	0	0	1	1	0
32		19	0	23	0	0	1	1	0
33		19	0	23	0	0	1	1	0
34		20	0	24	0	0	1	1	0
35		21	1	26	0	0	1	1	0
36		22	0	26	0	0	1	1	0
37		23	0	39	0	0	1	1	0
38		23	0	39	0	0	1	1	0
39		24	0	24	0	0	1	1	0
40		25	0	45	0	0	1	1	0
41		26	0	41	0	0	1	1	0
42		27	0	41	0	0	1	1	0
43		28	0	24	0	0	1	1	0
44		28	0	24	0	0	1	1	0
45		29	0	48	0	0	1	1	0
46		30	0	44	0	0	1	1	0
47		31			0	0	1	1	0
48		32	0	28	0	0	1	1	0
49		33	1	21	0	0	1	1	0
50		34	0	44	0	1	1	1	0
51		35	0	40	0	1	1	1	0
52		36	0	45	0	0	1	1	0
53		36	0	45	0	0	1	1	0
54		37	0	41	0	0	1	1	0
55		38	1	60	0	0	1	1	0
56		39	0	21	0	0	1	1	0
57		40	0	38	0	0	1	1	0
58		40	0	38	0	0	1	1	0
59	a1		0	46	0	0	1	1	0
60	a2		0	55	0	0	1	1	0
	a3		0	35	0	0	1	1	0

1									
2	a4	0	25	0	0	1	1	0	
3	a5	0	55	0	0	1	1	0	
4	a6	0	41	0	0	1	1	0	
5	a7	0	45	0	0	1	1	0	
6	a8	0	25	0	0	1	1	0	
7	a9	0	45	0	1	1	0	0	
8	a10	0		0	0	1	1	0	
9	a11	0	36	0	0	1	1	0	
10	a12	0	35	0	0	1	1	0	
11	a13	1	22	0	0	1	1	0	
12	a14	0	32	0	0	1	1	0	
13	a16	0	41	0	0	1	1	0	
14	a17	1	38	0	0	1	1	0	
15	a18	1	32	0	0	1	1	0	
16	a19	1	29	0	0	1	1	0	
17	a20	0	43	0	0	1	1	0	
18	a21	0	39	0	0	1	1	0	
19	a22	0	33	0	0	1	1	0	
20	a24	1	26	0	0	1	1	0	
21	a25	0	28	0	0	1	1	0	
22	a26	0	29	0	0	1	1	0	
23	a29	0	57	0	0	1	1	0	
24	a32	0	29	0	0	1	1	0	
25	a34	0	34	0	0	1	1	0	
26	a35	0	25	0	0	1	1	0	
27	a37	0	39	0	0	1	1	0	
28	a38	0	28	0	0	1	1	0	
29	a39	1	21	0	0	1	1	0	
30	a43	0	38	0	0	1	1	0	
31	Hospital4	0	0	66	1	0	0	1	0
32		2	0	33	1	0	0	1	0
33		5	1	29	0	0	0	1	0
34	Hospital5	1	1	26	0	0	0	1	0
35		2	0	21	0	0	0	1	0
36		3	1	35	0	0	0	1	0
37		4	0	37	0	0	0	1	0
38		5	0	20	0	0	0	1	0
39		6	0	16	0	0	0	1	0
40		7	0	38	0	0	0	0	0
41		8	0	2	0	0	0	1	0
42		9	1	44	0	0	0	1	0
43		10	0	39	0	0	0	1	0
44		11	1	24	0	0	0	1	0
45		12	0	18	0	0	0	1	0
46		13	0	24	0	0	0	1	0
47		14	1	1	0	0	0	1	0
48		15	1	25	0	0	0	1	0
49		16	0	25	0	0	0	0	0
50		17	0	19	0	0	0	1	0
51		18	1	21	0	0	0	1	0
52		19	0	21	0	0	0	1	0
53		20	1	22	0	0	0	1	0

1									
2		21	0	22	0	0	0	1	0
3		22	1	68	0	0	0	1	0
4		23	0	95	0	0	0	1	0
5		24	0	73	0	0	0	1	0
6		25	1	57	0	0	0	1	0
7		26	0	86	0	0	0	1	0
8		27	1	74	0	0	0	1	0
9		28	0	60	0	0	0	1	0
10		29	1	76	0	0	0	1	0
11		30	1	19	0	0	0	1	0
12		31	0	31	0	0	0	1	0
13		32	1	83	0	0	0	1	0
14		33	0	81	0	0	0	1	0
15		34	1	50	0	0	0	1	0
16		35	0	78	0	0	0	1	0
17		36	1	56	0	0	0	1	0
18		37	0	46	0	0	0	1	0
19		38	0	54	0	0	0	1	0
20		39	1	70	0	0	0	1	0
21		40	1	56	0	0	0	1	0
22									
23									
24									
25	Hospital6	0	1	57	0	0	0	1	0
26		2	0	51	0	0	0	1	0
27	Hospital7	1	1	48	0	0	1	1	0
28		2	0	26	0	0	1	1	0
29		3	1	26	0	0	1	1	0
30		4	0	50	0	0	1	1	0
31		5	1	30	0	1	0	1	1
32		6	1	67	0	1	0	1	1
33		7	1	25	0	1	0	1	1
34		9	0	30	0	1	1	1	0
35		10	0	35	0	1	1	1	0
36		11	0	46	0	0	1	1	0
37		12	0	51	0	0	1	1	0
38		13	0	44	0	0	1	1	0
39		14	0	33	0	0	0	1	0
40		15	0	32	0	0	1	1	1
41		16	0	45	0	0	1	1	0
42		17	0	31	0	0	1	1	1
43		18	0	34	0	0	1	1	1
44		19	0	42	0	0	1	1	0
45		20	0	26	0	0	1	1	1
46		21	1	25	0	0	1	1	0
47		22	0	26	0	0	1	1	0
48		23	0	35	0	0	1	1	0
49		24	0	30	0	0	1	1	0
50		25	0	32	0	0	1	1	0
51		26	0	26	0	0	1	1	0
52		27	0	29	0	0	1	1	0
53		28	0	35	0	0	1	1	0
54		29	1	26	0	0	1	1	0
55		30	0	31	0	0	1	1	0
56		31	0	21	0	0	1	1	0

1									
2		32	0	39	1	1	0	1	1
3		33	0	25	0	0	1	1	0
4		34	0	32	0	0	1	1	0
5		35	1	24	0	0	1	1	0
6		36	0	33	0	0	1	1	0
7		37	0	32	0	0	1	1	0
8		38	0	27	0	1	1	1	0
9		39	0	26	0	0	1	1	0
10		40	0	28	0	0	1	1	0
11		40	0	28	0	0	1	1	0
12	Hospital8	1	0	51	0	0	1	1	0
13		2	0	23	0	0	1	1	0
14		3		27	0	0	1	1	0
15		4		29	0	0	1	1	0
16		5		42	0	0	1	1	0
17		6	0	48	0	0	1	1	0
18		7	0	31	0	0	1	1	0
19		8	0	23	0	0	1	1	0
20		9	0		0	0	1	1	0
21		9	0		0	0	1	1	0
22		10			0	0	1	1	0
23		11	0	51	0	0	1	1	0
24		12	0	48	0	0	1	1	0
25		13	0	26	0	0	1	1	0
26		14	0	46	0	0	1	1	0
27		15	1	37	0	0	1	1	0
28		16	1	37	0	0	1	1	0
29		17	1	41	0	0	1	1	0
30		18	0	28	0	0	1	1	0
31		19	0	34	0	0	1	1	0
32		20	0	56	0	0	1	1	0
33		21	1	56	0	0	1	1	0
34		22	0	28	0	1	1	1	0
35		23	0	30	0	0	1	1	0
36		24	1	26	0	0	1	1	0
37		25	1	36	0	0	1	1	0
38		26	0	27	0	0	1	1	0
39		27	1	27	0	0	1	1	0
40		28	1		0	0	1	1	0
41		29	0	53	0	0	1	1	0
42		30	0	48	0	0	1	1	0
43		31	0	47	0	0	1	1	0
44		32	0		0	0	1	1	0
45		33	0	31	0	0	1	1	0
46		34	0	31	0	1	1	0	0
47		35	0	37	0	0	1	1	0
48		36	0	50	0	1	1	1	0
49		37		24	0	1	1	1	0
50		38	0	30	0	1	1	1	0
51		39	0	49	0	0	1	1	0
52		40	0	36	0	0	1	1	0
53		40	0	36	0	0	1	1	0
54		1	1	27	0	1	1	1	0
55	Hospital9	2	0	44	0	1	1	1	0
56		3	1	29	0	1	1	1	0
57									
58									
59									
60									

1									
2		4	0	44	0	0	1	1	0
3		5	1	56	1	1	1	1	0
4		6	0	62	0	0	0	1	0
5		7	1	32	0	0	0	1	0
6	Hospital10	1	0	23	0	0	1	1	0
7		2	0	26	0	1	1	1	0
8		3	0	51	0	1	1	1	0
9		4	0	29	0	0	1	1	0
10		5	0	45	0	0	1	1	0
11		6	0	44	0	1	1	1	0
12		7	0	29	0	1	1	1	0
13		8	0	28	0	1	1	1	0
14		9	0	50	0	0	0	1	0
15		10	1	38	0	1	1	1	0
16		11	0	39	0	1	1	1	0
17		12	0	28	0	1	1	1	0
18		13		21	0	1	1	1	0
19		14	0	24	0	1	1	1	0
20		15	0	38	0	1	1	1	0
21		16	1	28	0	1	1	1	0
22		17	0	55	0	1	1	1	0
23		18	0	39	0	0	1	1	0
24		19	0	48	0	0	1	1	0
25		20	0	42	0	0	1	1	0
26		21	0	33	0	0	1	1	0
27		22	1	48	0	0	1	1	0
28		23	0	39	0	0	1	1	0
29		24	1	29	0	0	1	1	0
30		25	0	25	0	0	1	1	0
31		26	1	31	0	0	1	1	0
32		27	1	56	0	0	1	1	0
33		28	0	22	0	0	1	1	0
34		29			0	0	0	0	0
35		30	0	60	0	0	0	1	0
36		31	0	25	0	0	0	1	0
37		32	0	23	0	0	0	1	0
38		33	1	23	0	0	0	1	0
39		34	0	53	0	0	0	1	0
40		35	0	54	0	0	0	1	0
41	Hospital11	1	1	53	0	0	1	1	0
42		2	0	36	0	0	1	1	0
43		3	0	22	0	1	1	1	0
44		4	0	39	0	0	1	1	0
45		5	1	36	0	0	1	1	0
46		6	0	53	0	0	1	1	0
47		7	0	42	0	1	1	1	0
48		8	0	25	0	0	1	1	0
49		9	0	34	0	1	1	1	1
50		10	1	36	0	0	1	1	0
51		11	1	40	0	0	1	1	0
52		12	1	59	0	0	1	1	0
53		13	0	26	0	0	1	1	0

1									
2		14	0	40	0	0	1	1	0
3		15	0	51	0	0	1	1	0
4		16	0	43	0	0	1	1	0
5		17	0	41	0	0	1	1	0
6		18	0	47	0	0	1	1	0
7	Hospital12	1	0	29	0	0	1	1	0
8	Hospital13	1	0	41	0	0	1	1	0
9		2	0	42	0	1	1	1	0
10		3	1	26	0	1	1	1	0
11		4	1		0	1	1	1	0
12		5	0	45	1	0	1	1	0
13		6	0	56	0	1	1	1	0
14		7	0		0	1	1	1	0
15		8	0	53	0	1	1	1	0
16		9	0	44	0	1	1	1	0
17		10	0	48	0	1	1	1	0
18		11	0	38	0	1	1	1	0
19		12	0	57	0	1	1	1	0
20		13	1	25	1	0	0	1	1
21		14	1	26	0	0	1	1	1
22	Hospital14	0	1	66	0	0	0	1	0
23		1	0	60	0	0	1	1	0
24		2		38	1	1	1	1	0
25		3	0	39	0	0	1	1	0
26		4	0	17	0	0	0	1	0
27		5	0	18	0	1	0	1	0
28		6	0	30	0	0	1	1	0
29		7	0	42	0	0	1	1	0
30		8	1	58	1	0	0	1	1
31		9	1	60	1	0	0	1	0
32		10	1	39	0	0	1	1	0
33		11	0	38	1	0	1	1	0
34		12	0	15	0	0	0	1	0
35		13	0	49	0	0	0	1	0
36		14	1	40	1	0	0	1	0
37		15	1	43	0	0	1	1	0
38		16	0	42	0	0	1	1	0
39		17	0	9	1	0	0	1	0
40		18	1	39	0	0	1	1	0
41		19	0	48	0	0	1	1	0
42		20	0	30	0	0	1	1	0
43		21	1	28	0	0	1	1	0
44		22	0	28	0	0	1	1	0
45		23	0	43	0	1	1	1	0
46		24	1	63	0	0	0	1	0
47		25	0	31	0	0	1	1	1
48		26	0	42	0	0	1	1	0
49		27	0	44	0	0	1	1	0
50		28	0	26	0	0	1	1	0
51	Hospital15	1	1	27	0	0	1	1	0
52		2	0	42	0	0	1	1	0
53		3	0	41	0	0	1	1	0

1									
2		4	0	31	0	0	1	1	0
3		5	0	31	0	0	1	1	0
4		6	1	32	0	0	1	1	0
5		7	0	24	0	0	1	1	0
6		8	0	43	0	0	0	1	0
7		9	0	24	0	0	1	1	0
8		10	0	27	0	0	1	1	0
9		11	0	33	0	0	0	1	0
10		12	1	56	0	0	1	1	0
11		13	0	26	0	0	1	1	0
12		14	1	21	0	0	1	1	0
13		15	0	35	0	0	1	1	0
14		16	1	49	0	0	0	1	0
15		17	0	43	0	0	1	1	0
16		18	0	34	0	0	1	1	0
17		19	0	26	1	0	0	1	0
18		20	0	31	0	0	1	1	0
19		21	0	33	0	0	1	1	0
20		22	0	30	0	0	1	1	0
21		23	1	42	0	0	0	1	0
22		24	0	28	0	0	1	1	0
23		25	0	46	0	0	1	1	0
24		26	0	33	0	0	1	1	0
25		27	0	31	0	0	1	1	0
26		28	0	44	0	0	0	1	0
27		29	0	44	0	0	1	1	0
28		30	0	30	0	0	1	1	0
29		31	0	35	0	0	1	1	0
30		33	1	31	0	0	1	1	1
31		34	0	30	0	0	1	1	0
32		35	0	25	0	0	1	1	0
33		36	1	28	1	0	1	1	0
34		37	0		0	0	1	1	0
35	Hospital16	1	0	40	0	1	1	1	1
36		2	1	34	0	1	1	1	1
37		3	0	37	0	1	1	1	1
38		4	0	31	0	1	1	1	1
39		5	0	44	0	1	1	1	1
40		6	1	37	0	1	1	1	1
41		7	1	22	0	1	1	1	1
42		8	0	36	0	1	1	1	1
43		9	1	40	0	1	1	1	1
44		10	0	40	0	1	1	1	1
45		11	0	45	0	1	1	1	1
46		12	0	28	0	1	1	1	1
47		13	1	27	0	1	1	1	1
48		14	0	56	0	1	1	1	1
49		15	0	49	0	1	1	1	1
50		16	0	41	0	1	1	1	0
51		17	1	32	0	1	1	1	1
52		18	0	29	0	1	1	1	1
53		19	0	47	0	1	1	1	1

1									
2		20	0	29	0	1	1	1	1
3	Hospital17	1	0	49	0	1	1	1	0
4		2	0	26	0	0	0	1	0
5		3	0	49	0	0	0	1	0
6		4	0	28	1	0	1	1	0
7		5	0	24	0	0	1	1	0
8		6	0	34	1	0	1	1	0
9		7	0	30	0	0	1	1	0
10		8	0	28	0	0	1	1	1
11		9	0	31	0	0	0	1	0
12		10	0	31	0	0	1	1	0
13		11	0	31	0	0	0	1	0
14		12	0	37	0	1	1	1	0
15		13	0	27	0	1	1	1	0
16		14	0	34	0	1	1	1	0
17		15	0	33	0	0	1	1	0
18		16	1	53	0	1	1	1	0
19		17	0	54	0	0	1	1	0
20		18	1	58	0	0	1	1	0
21		19	0	41	0	0	0	1	0
22		20	0	39	0	0	0	1	0
23		21	0	23	0	0	0	1	0
24		22	0	31	0	0	0	1	0
25		23	0	46	0	0	0	1	0
26		24	1	27	0	1	1	1	0
27		25	1	27	0	0	1	1	0
28		26	0	48	0	0	1	1	0
29	Hospital18	2	0	26	0	0	1	1	0
30		3	0	52	0	0	1	1	0
31		4	0	41	0	0	1	1	0
32		5	0	30	0	0	1	1	0
33		6	0	53	0	0	1	1	0
34		7	1	33	0	0	1	1	0
35		8	0	53	0	0	1	1	0
36		9	0	40	0	0	1	1	0
37		10	0	48	0	0	1	1	0
38		11	0	52	0	0	1	1	0
39		12	1	27	0	0	1	1	0
40		13	1	40	0	0	1	1	0
41		14	0	24	0	0	1	1	0
42		15	0	40	0	0	1	1	0
43		16	0	37	0	0	1	1	0
44		17	0	37	0	0	0	1	0
45		18	0	53	0	0	0	1	0
46		19	0	57	0	0	1	1	0
47		20	0	55	0	0	1	1	0
48	Hospital19	1	0	80	0	0	0	1	1
49		2	1	30	0	0	0	1	1
50		3	1	30	1	0	0	1	1
51		4	1	47	1	0	0	1	1
52		5	0		0	1	0	1	1
53		6	1	77	0	0	0	1	1

1									
2		7	1	24	1	0	0	1	1
3		8	1	35	1	0	0	1	1
4		9	1	31	1	0	0	1	1
5		10	1	37	1	0	0	1	1
6		11	0	60	1	0	0	1	1
7		12	0	32	1	0	0	1	1
8		13	1	34	1	0	0	1	1
9		14	0	26	1	0	0	1	1
10		15	1	39	1	0	0	1	1
11		16	0	46	1	0	0	1	1
12		17	0	3	1	0	0	1	1
13		18	0	81	1	0	0	1	1
14		19	1	19	0	0	0	1	1
15		20	0	61	0	0	0	1	1
16		21	0	61	0	0	0	1	1
17		22	0	61	0	0	0	1	1
18	Hospital20	1	0	57	0	0	1	1	0
19		2	1	38	0	0	1	1	0
20		3	1	56	0	0	1	1	0
21		4	0	56	0	0	1	1	0
22		5	0	42	0	0	1	1	0
23		6	0	47	0	0	1	1	0
24		7	0	58	0	0	1	1	0
25		8	0	57	0	0	1	1	0
26		9	0	53	0	0	1	1	0
27		10	0	53	0	0	1	1	0
28	Hospital21	1	0	18	0	0	0	1	0
29		2	0		1	0	0	1	0
30		3	0	28	1	0	0	1	0
31	Hospital22	1	0	59	0	0	0	1	0
32		2	1	72	0	0	0	1	0
33		3	1	70	0	0	0	1	0
34		4	0	10	0	0	0	1	1
35		5	0	66	0	0	0	1	0
36		6	0	66	0	0	0	1	0
37	Hospital23	1	0	28	0	0	1	1	0
38		2	0	22	0	0	1	1	0
39		3	1	41	0	0	1	1	0
40		4	0	34	0	0	1	1	0
41		5	0	29	0	0	1	1	0
42		6	0	38	0	0	1	1	0
43		7	0	37	0	0	1	1	0
44		8	0	43	0	0	1	1	0
45		9	0	53	0	0	1	1	0
46		10	0	38	0	0	1	1	0
47		11	1	39	0	0	1	1	0
48		12	0	48	0	0	0	1	0
49		13	0	31	0	0	1	1	0
50		14	0	44	0	0	0	1	0
51		15	0	40	0	0	0	1	0
52		16	0	37	0	0	0	1	0
53		17	0	24	0	0	1	1	0
54		18	0	25	0	0	1	1	0
55		19	1		0	0	1	1	0
56		20	1	44	0	0	0	1	0
57		21	1	44	0	0	0	1	0
58		22	1	54	0	0	0	1	0
59	Hospital24	1	1	54	0	0	0	1	0
60									

1								
2	2	1	57	0	0	1	1	1
3	3	0	45	0	0	1	1	0
4	4	0	52	0	0	1	1	0
5	5	0	37	0	0	1	1	0
6	6	0	44	0	0	1	1	0
7	7	0	23	0	1	1	1	0
8	8	0	23	0	1	0	1	0
9	9	1	40	0	0	1	1	0
10	10	0		0	0	1	1	0
11	11	0	53	0	1	1	1	0
12	12	0	43	0	1	1	1	0
13	13	0	29	0	1	1	1	0
14	14	0	25	0	1	1	1	0
15	15	0	25	0	1	1	1	0
16	16	1	38	0	1	1	1	0
17	17	0	55	0	1	1	1	0
18	18	0	59	0	0	1	1	0
19	19	0	52	0	0	1	1	0
20	20	1	23	0	0	1	1	0
21								
22								
23								
24	Hospital25	1	44	0	0	1	1	0
25		2	37	0	1	1	1	1
26		3	42	0	1	1	1	1
27		4	47	0	1	1	1	1
28		5	42	0	1	1	1	1
29		6	46	0	1	0	1	1
30		7	42	0	1	0	1	1
31		8	26	0	1	1	1	1
32		9	51	0	1	1	1	1
33								
34		10	27	0	1	1	1	1
35		11	25	0	1	1	1	1
36		12	26	0	0	1	1	1
37		13	26	0	1	1	1	1
38		14	35	0	1	1	1	1
39		15	28	0	0	1	1	1
40		16	23	0	0	1	1	1
41		17	23	0	0	1	1	1
42		18	43	0	1	1	1	1
43		19	54	0	0	0	1	0
44								
45	Hospital26	1	45	0	0	1	1	0
46		2	48	0	0	1	1	0
47		3	56	0	0	1	1	0
48		4	45	0	0	1	1	0
49		5	42	0	0	1	1	0
50		6	42	0	0	1	1	0
51		7	46	0	0	1	1	0
52		8	30	0	0	1	1	0
53		9	24	0	0	1	1	0
54		10	25	0	0	1	1	0
55		11	22	0	0	1	1	0
56		12	29	0	0	1	1	0
57		13	40	0	0	1	1	0
58		14	42	0	0	1	1	0
59								
60								

1									
2		15	0	40	0	0	1	1	0
3		16	1	46	0	0	1	1	0
4		17	1	35	0	0	1	1	0
5		18	1	41	0	0	1	1	0
6		19	0	38	0	0	1	1	0
7		20	1	56	0	0	1	1	0
8									
9	Hospital27	1	1	25	0	0	0	1	0
10	Hospital28	1	0	26	0	0	1	1	0
11		2	1	27	0	0	1	1	0
12		3	1	25	0	0	1	1	0
13		4	0	27	0	0	1	1	0
14		5	1	47	0	0	1	1	0
15		6	1	36	0	0	1	1	0
16		7	0	38	0	0	1	1	0
17		8	0	26	0	1	1	1	0
18		9	0	27	0	0	1	1	0
19		10	0	25	0	0	1	1	0
20		11	0	32	0	0	1	1	0
21		12	0	27	0	0	1	1	0
22		13	0	48	0	0	1	1	0
23		14	1	48	0	0	1	1	0
24		15	0	51	0	0	1	1	0
25		17	1	42	0	1	1	1	0
26		18	0	33	0	0	1	1	0
27		19	0	44	0	0	1	1	0
28		20	1	35	0	0	1	1	0
29									
30									
31	Hospital29	1	0	36	0	0	1	1	0
32		2	0	40	0	0	1	1	0
33		3	0		0	0	1	1	0
34		4	0	59	0	0	1	1	0
35		5	0	42	0	0	1	1	0
36		6	0	26	0	0	1	1	0
37		7	0	28	1	0	1	1	0
38		8	0	24	0	0	1	1	0
39									
40									
41	Hospital30	1	0	19	1	0	0	1	1
42		2	0	27	0	0	1	1	1
43		3	0	26	0	0	1	1	0
44		4	0	25	0	0	1	1	0
45		5	1	26	0	0	1	1	0
46		6	1	25	1	0	1	1	1
47		7	0	25	0	0	1	1	0
48		8	0	50	0	0	1	1	0
49		9	1	59	0	0	1	1	0
50		10	1	40	0	0	1	1	0
51		11	1	37	0	0	1	1	0
52		12	0	25	0	0	1	1	0
53		13	0	25	0	0	1	1	0
54		14	1	53	0	0	1	1	0
55		15	0	45	0	0	1	1	0
56									
57									
58	Hospital31	1	0	33	0	0	1	1	0
59		2	1	31	0	0	1	1	0
60		3	0	24	0	0	1	1	0

1									
2		5	0	53	0	0	1	1	0
3		6	0	42	0	1	1	0	1
4		7	0	23	0	0	1	1	0
5		8	0	53	0	0	1	1	0
6		9	1	34	0	0	1	1	0
7		10	0	23	0	0	0	1	0
8		11	0	38	0	1	1	1	0
9		12	1	26	0	0	1	1	0
10		13	0	46	0	0	1	1	0
11		14	0	29	0	0	1	1	0
12		15	0	26	0	0	1	1	0
13		16	0	27	0	0	1	1	0
14		17	0	45	0	1	1	1	0
15		19	0	25	0	0	1	1	0
16		20	0	59	0	0	1	1	0
17		21	0	46	0	1	1	1	0
18		22	0	38	0	1	1	1	0
19		21	0	46	0	1	1	1	0
20		22	0	38	0	1	1	1	0
21	Hospital32	1	0	30	0	0	1	1	1
22		2	0	28	0	0	0	1	0
23		3	0	38	0	0	1	1	0
24		4	0	40	0	0	1	1	0
25		5	0	32	0	0	1	1	0
26		6	0	33	0	0	1	1	0
27		7	0	36	0	0	1	1	0
28		8	0	27	0	0	1	1	0
29		9	0	27	0	0	1	1	0
30		10	1	39	0	0	1	1	0
31		11	0	33	0	0	1	1	0
32		12	0	33	0	0	1	1	0
33		13	0	49	0	0	1	1	0
34		14	0	42	0	0	1	1	0
35		15	0	30	0	0	1	1	0
36		16	0	26	0	0	1	1	0
37		17	0	46	0	0	1	1	0
38		18	0	37	0	0	1	1	0
39		19	0	46	0	0	1	1	0
40		20	0	31	0	0	1	1	0
41	Hospital33	1	0	28	0	0	1	1	0
42		2	1	34	0	0	1	1	0
43		3	0	22	0	0	1	1	0
44		4	0	40	0	0	1	1	0
45		5	1	50	0	0	1	1	0
46		6	0	58	0	0	1	1	0
47		7	0	44	0	0	1	1	0
48		8	0	51	0	0	1	1	0
49		9	0	27	0	0	1	1	0
50		10	0	26	0	0	1	1	0
51		11	0	24	0	0	1	1	0
52		12	0	46	0	0	1	1	0
53		13	1	52	0	0	1	1	0
54		14	0	32	0	0	1	1	0
55		15	0	43	0	0	1	1	0

1									
2		16	0	27	0	0	1	1	0
3		17	0	34	0	0	1	1	0
4		18	1	37	0	0	1	1	0
5		19	1	26	0	0	1	1	0
6		20	1	43	0	0	1	1	0
7	Hospital34	1	1	26	0	1	1	1	0
8		2	1	45	0	0	0	1	0
9		3	0	45	0	0	0	1	0
10		4	0	23	0	1	1	1	0
11		5	0	26	0	0	1	1	0
12		6	0	24	0	0	1	1	0
13		7	0	39	1	0	1	1	0
14		8	0	23	0	0	1	1	0
15		9	0	26	1	0	1	1	0
16		10	0	31	0	0	1	1	0
17		11	0	22	1	0	1	1	0
18	Hospital35	1	0	43	0	0	1	1	0
19		2	0	45	0	0	1	1	0
20		3	0	37	0	0	1	1	0
21		4	0	45	0	0	1	1	0
22		5	0	46	0	0	1	1	0
23		6	0	28	0	0	1	1	0
24		7	0	25	0	0	1	1	0
25		8	0	26	0	0	1	1	0
26		9	1	50	0	0	1	1	0
27		10	0	36	0	0	1	1	0
28		11	0	43	0	0	1	1	0
29		12	0	25	0	0	1	1	0
30		13	0	31	0	0	1	1	0
31		14	0	33	0	0	1	1	0
32		15	1	50	0	0	1	1	0
33		16	1	52	0	0	1	1	0
34		17	1	59	0	0	1	1	0
35		18	1	35	0	0	1	1	0
36		19	0	41	0	0	1	1	0
37		20	0	34	0	0	1	1	0
38	Hospital36	1	0	51	0	0	1	1	1
39		2	0	55	0	0	1	1	1
40		3	0	55	0	0	1	1	1
41		4	0	42	0	0	1	1	1
42		5	0	40	0	0	1	1	1
43		6	1	43	0	0	1	1	1
44		7	0	43	0	0	1	1	1
45		8	0	49	0	0	1	1	1
46		9	0	54	0	0	1	1	1
47		10	0	47	0	0	1	1	1
48		11	1	40	0	0	1	1	1
49		12	1	56	0	0	1	1	1
50		13	1	53	0	0	1	1	0
51		14	0	51	0	0	1	1	1
52		15	1	38	0	0	1	1	1
53		16	0	23	0	0	1	1	1
54									
55									
56									
57									
58									
59									
60									

1									
2		17	1	28	0	0	1	1	1
3		18	0	40	0	0	1	1	1
4		19	0	33	0	0	1	1	1
5		20	0	35	0	0	1	1	0
6	Hospital37	1	1	51	0	1	1	1	0
7		2	1	45	1	1	1	1	0
8		3	0	28	0	1	1	1	0
9		4	0		0	0	1	1	0
10		5	0	36	0	0	1	1	0
11		6	0	41	0	0	1	1	0
12		7	0	45	0	0	0	1	0
13		8	0	24	0	0	1	1	0
14		9	0	46	0	0	1	1	0
15		10	0	23	0	0	1	1	0
16		11	0	23	0	0	0	1	0
17		12	0	24	0	1	1	1	0
18		13	0	22	0	1	1	1	0
19		14	0	23	1	1	1	1	0
20		15	1	44	0	0	1	1	1
21	Hospital38	1	1	26	1	0	1	1	1
22		2	0	25	1	1	1	1	0
23		3	1	54	0	1	1	1	0
24		5	0	54	0	0	1	1	0
25		6	0	39	0	0	1	1	0
26		7	0	55	0	0	1	1	0
27		8	0	54	0	0	1	1	0
28		9	0	45	0	0	1	1	0
29		10	0	37	0	0	1	1	0
30		11	0	55	0	0	1	1	0
31		12	0	23	0	0	1	1	0
32		13	0	25	0	0	1	1	0
33		14	0	42	0	0	1	1	0
34		15	0	56	0	0	1	1	0
35		16	1	52	0	0	1	1	0
36		17	0	54	0	0	1	1	1
37		18	1	52	0	0	1	1	0
38		19	0	24	0	0	1	1	1
39		20	0	57	0	0	1	1	0
40	Hospital39	1	1	53	0	0	1	1	0
41		2	1	41	0	0	1	1	0
42		3	1	32	0	0	1	1	0
43		5	1	31	0	0	1	1	0
44		7	0	57	0	0	1	1	0
45		8	0	44	0	0	1	1	0
46		9	0	47	0	0	0	1	0
47		10	1	49	0	0	1	1	0
48		11	0	32	0	0	1	1	0
49		12	0	27	0	0	0	1	0
50		13	0	38	0	0	1	1	0
51		14	1	28	0	0	0	1	0
52		15	0	28	0	0	0	1	0
53		16	0	44	0	0	1	1	0
54									
55									
56									
57									
58									
59									
60									

1									
2		17	0	43	0	0	0	1	0
3		18	0	43	0	0	0	1	0
4		19	0	32	0	0	1	1	0
5		20	1	25	0	0	1	1	0
6	Hospital40	1	0	34	0	0	0	0	0
7		2	1	27	0	0	1	1	0
8		3	0	43	0	0	1	1	0
9		4	0	29	0	0	0	1	0
10		5	0	23	0	0	1	1	0
11		6	0	48	0	1	1	1	0
12		7	0	34	0	0	1	1	0
13		1	0	34	0	0	0	1	1
14	Hospital41	2	0	24	0	0	0	1	1
15		3	0	33	0	0	0	1	1
16		4	0	41	0	0	0	1	1
17		5	0	29	0	0	0	1	1
18		6	0	34	0	0	0	1	1
19		7	0	17	0	0	0	1	1
20		8	0	37	0	0	0	1	1
21		1	1	63	0	0	0	1	0
22	Hospital42	2	1	63	0	0	0	1	1
23		3	1	63	0	0	0	1	1
24		4	0	54	0	0	0	1	0
25		5	1		0	0	0	1	0
26		6	0	41	0	0	0	1	0
27		7	0		0	0	0	1	0
28		8	0	43	0	0	1	1	0
29	Hospital43	1	0	33	0	0	1	1	0
30		5	0	45	0	0	1	1	0
31		6	0	43	0	0	1	1	0
32	Hospital44	1	1	19	0	0	0	1	0
33	Hospital45	1	1	42	0	0	0	1	0
34		2	1	44	0	1	0	1	0
35	Hospital46	1	0	71	0	0	0	1	0
36	Hospital47	1	0	32	0	0	1	1	0
37		2	1	45	0	0	1	1	0
38		3	1	24	0	0	1	1	0
39		4	0		0	0	1	1	0
40		5	0	43	0	0	1	0	0
41		6	0	30	0	0	1	1	0
42		7	0	27	0	0	1	1	0
43		8	0	40	0	0	1	1	0
44		9	0	41	0	0	1	1	0
45		10	1	48	0	0	1	1	0
46		11	0	47	0	0	1	1	0
47		12	0		0	0	0	0	0
48	Hospital48	1	1	26	1	0	1	1	0
49		2	0	26	1	0	1	1	0
50		3	0	25	0	0	1	1	0
51		4	1	25	1	0	1	1	0
52		5	0	46	0	0	1	1	0
53		6	0	32	0	0	1	1	0

1									
2	Hospital49	1	0	51	0	0	1	1	0
3		3	0	46	0	0	1	1	0
4		4	1	27	0	0	1	1	0
5		5	0	25	0	0	1	1	0
6		7	0	31	0	0	1	1	0
7		9	0	37	0	0	1	1	0
8		10	0	31	0	0	1	1	0
9		11	1	21	0	0	1	1	0
10		13	0	41	0	1	1	1	0
11		14	0	33	0	1	1	1	0
12		15	0	32	0	1	1	1	1
13		16	0	32	0	1	1	1	0
14		17	0	40	0	1	1	1	0
15		18	0	41	0	1	1	1	0
16		19	0	45	0	1	1	1	0
17		20	0	33	0	1	1	1	0
18		20	0	33	0	1	1	1	0
19	Hospital50	1	1	11	1	0	0	1	1
20	Hospital51	1	1	26	1	0	0	1	0
21		2	0	33	1	0	0	1	1
22		3	0	21	1	0	0	1	1
23	Hospital52	1	1	29	0	0	1	1	1
24		2	0	15	0	0	0	1	1
25		3	0	23	1	0	0	1	1
26		4	0	9	0	0	0	0	1
27		5	0	34	0	0	0	1	1
28		6	0	60	0	0	0	1	0
29									
30									
31									
32									
33									
34									
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									
47									
48									
49									
50									
51									
52									
53									
54									
55									
56									
57									
58									
59									
60									

	IgM	IgG	IgM or IgG	Symptomat	Fever	Cough	Sneeze	Sore Throat	Dyspnea	
1										
2										
3		0	0	0	1	0	0	0	1	0
4		0	0	0	0	0	0	0	0	0
5		0	0	0	1	0	1	0	0	0
6	1	0	1	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0
8	0	0	0	0	1	1	0	0	1	0
9	1	0	1	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0
11	1	0	1	1	1	1	1	1	1	0
12	1	0	1	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0
16	1	0	1	0	0	0	0	0	0	0
17	1	0	1	0	0	0	0	0	0	0
18	1	0	1	0	0	0	0	0	0	0
19	1	0	1	0	0	0	0	0	0	0
20	1	0	1	1	0	0	0	0	1	0
21	0	0	0	1	0	0	1	0	1	0
22	0	0	0	0	0	0	0	0	0	0
23	0	0	0	1	1	1	1	1	1	0
24	0	0	0	1	0	0	0	1	1	0
25	1	0	1	1	0	0	1	0	1	1
26	0	0	0	1	1	0	0	0	0	1
27	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0
30	0	0	0	1	0	1	0	0	0	0
31	0	0	0	0	0	0	0	0	0	0
32	0	0	0	1	1	1	1	1	0	0
33	0	0	0	1	0	1	0	0	1	0
34	0	0	0	1	1	0	1	0	0	0
35	0	0	0	1	0	0	0	0	1	0
36	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0
42	0	0	0	1	0	1	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0	0
49	0	0	0	1	0	0	0	1	0	0
50	0	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0	0
52	0	0	0	1	0	1	0	0	0	0
53	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0	0
59	0	0	0	1	0	0	0	0	1	0
60	0	0	0	1	0	1	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	1	0	0	1	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	1	0	1	0	0	0	0	0	0
23	1	0	1	1	0	1	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	1	0	1	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	1	0	1	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	1	0	1	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	1	0	0	1	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	1	0	0	0	1	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	1	0	0	0	1	0
49	0	0	0	1	0	1	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	1	0	1	1	0	0
14	0	0	0	1	0	1	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	1	0	1	1	0	0	0	0	1
37	1	0	1	1	1	1	0	1	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	1	0	1	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	1	1	0	0	0	0
5	0	0	0	1	0	0	0	0	1
6	0	0	0	1	0	1	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	1	0	1	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	1	1	0	0	0	1
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	1	0	1	0	0	0	0	0	0
29	0	0	0	1	0	0	1	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	1	0	1	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	1	0	1	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	1	0	1	0	1	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	1	0	1	0	0	0
59	0	0	0	1	0	0	0	0	1
60	0	0	0	1	0	0	1	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	1	0	1	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	1	0	0	1	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	1	0	1	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	1	0	0	0	1	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	1	1	0	0	1	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	1	0	1	0	0	0
22	0	0	0	1	1	0	0	0	0
23	0	0	0	1	1	1	1	1	0
24	0	0	0	1	1	1	0	0	1
25	0	0	0	1	1	1	1	1	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	1	1	0	0	1	1
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	1	0	0	0	0	1
34	0	0	0	1	0	1	0	1	1
35	0	0	0	1	0	1	1	0	0
36	0	0	0	1	0	1	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	1	1	1	0	1	0
39	0	0	0	1	1	1	0	1	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	1	1	0	0	0	0
42	0	0	0	1	1	1	1	1	0
43	0	0	0	1	0	0	1	0	0
44	0	0	0	1	0	0	1	0	0
45	0	0	0	1	0	0	1	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	1	1	1	0	0	1
53	0	0	0	1	0	0	1	0	0
54	0	0	0	1	0	1	1	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	1	0	0	0	1	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	1	0	0	1	0	0
43	0	0	0	1	0	1	0	1	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	1	0	1	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	1	0	1	1	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	1	0	1	0	1	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	1	0	1	0	0	0
56	0	0	0	1	0	0	1	1	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	1	0	1	1	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	1	1	0	0	0	0
4	0	0	0	1	0	0	0	0	1
5	0	0	0	1	0	0	1	0	0
6	0	0	0	1	1	0	0	0	0
7	0	0	0	1	0	0	0	1	0
8	0	0	0	1	0	0	0	1	0
9	0	0	0	1	0	1	0	0	0
10	0	0	0	1	0	1	0	0	0
11	0	0	0	1	1	0	0	0	0
12	0	0	0	1	0	0	1	0	0
13	0	0	0	1	0	0	0	1	0
14	0	0	0	1	0	0	1	0	0
15	0	0	0	1	0	0	0	1	0
16	0	0	0	1	0	1	0	0	0
17	0	0	0	1	0	0	0	0	0
18	0	0	0	1	0	0	0	1	0
19	0	0	0	1	0	1	0	0	0
20	0	0	0	1	0	1	1	0	0
21	0	0	0	1	0	1	0	0	0
22	0	0	0	1	0	0	1	0	0
23	0	0	0	1	0	1	1	0	0
24	0	0	0	1	0	0	0	0	1
25	0	0	0	1	0	0	0	0	1
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	1	0	0	0	0	1
29	0	0	0	1	0	1	0	0	0
30	0	0	0	1	0	1	1	1	0
31	0	0	0	1	0	1	0	0	0
32	0	0	0	1	0	0	1	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	1	0	1	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	1	1	0	0	0	1
56	0	0	0	1	1	0	0	1	0
57	0	0	0	1	1	1	0	0	1
58	0	0	0	0	0	0	0	0	0
59	0	0	0	1	1	1	1	1	1
60	0	0	0	1	0	1	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	1	1	1	1	0	1
15	0	0	0	1	1	0	0	0	0
16	0	0	0	1	1	1	0	1	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	1	0	0	1	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	1	0	0	1	0	0
22	0	0	0	1	0	1	1	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	1	1	1	0	1	0
29	0	0	0	1	0	0	0	0	1
30	0	0	0	0	0	0	0	0	0
31	0	0	0	1	0	1	1	0	0
32	0	0	0	1	0	1	0	1	1
33	0	0	0	1	0	1	1	0	0
34	0	0	0	1	1	0	0	0	0
35	0	0	0	1	1	0	0	0	0
36	1	0	1	1	1	0	0	0	1
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	1	1	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	1	0	1	1	1	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	1	1	1	1	1	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	1	1	0	0	0	0
4	0	0	0	1	0	1	0	1	0
5	0	0	0	1	0	1	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	1	0	0	1	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	1	0	0	0	1	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	1	0	0	1	0	0
18	0	0	0	1	0	0	1	0	0
19	0	0	0	1	0	0	1	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	1	0	0	1	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	1	0	1	1	0	0	1	1	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	1	0	0	1	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	1	0	1	1	1	0	0	1	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	1	0	0	1	0	0
16	0	0	0	1	0	1	1	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	1	0	0	0	1	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	1	0	0	0	1	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	1	0	1	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	1	0	1	0	1	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	1	1	1	1	0	0	0	1	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	1	0	1	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	1	0	1	1	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	1	0	1	1	1	0
58	0	0	0	1	0	0	0	1	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	1	1	1	1	1	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	1	0	1	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	1	0	1	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	1	0	1	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	1	0	1	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	1	0	1	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	1	0	1	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	1	0	0	1	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	1	1	1	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	1	0	1	0	0	0
22	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0
38	0	0	0	1	0	0	0	1	0
39	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	1	0	1	0	0	0	0	0	0
47	1	0	1	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0
49	0	0	0	1	0	0	1	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	1	0	1	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	1	0	0	1	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	1	0	1	0	0	0	0	0	0
17	1	1	1	0	0	0	0	0	0
18	1	0	1	0	0	0	0	0	0
19	1	0	1	1	0	1	1	1	1
20	1	0	1	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
22	1	0	1	0	0	0	0	0	0
23	1	0	1	1	1	1	1	0	1
24	1	0	1	1	1	1	1	0	1
25	1	0	1	1	1	1	1	0	1
26	1	0	1	1	1	1	1	0	1
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0
33	0	0	0	1	1	1	1	0	0
34	1	0	1	0	0	0	0	0	0
35	1	0	1	0	0	0	0	0	0
36	0	0	0	1	1	1	0	1	0
37	1	0	1	1	0	0	0	0	1
38	0	0	0	1	1	1	0	0	1
39	1	0	1	1	0	1	0	1	1
40	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0
47	1	0	1	0	0	0	0	0	0
48	1	0	1	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0
56	0	0	0	1	0	0	1	0	0
57	0	0	0	0	0	0	0	0	0
58	0	0	0	1	0	0	1	0	0
59	0	0	0	0	0	0	0	0	0
60	0	0	0	0	0	0	0	0	0

1									
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0
10	1	0	1	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0
20	0	0	0	1	1	0	0	0	1
21	0	0	0	0	0	0	0	0	0
22	0	0	0	1	1	0	1	0	0
23	0	0	0	1	1	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0
29	0	0	0	1	1	1	0	0	0
30	1	0	1	0	0	0	0	0	0
31									
32									
33									
34									
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									
47									
48									
49									
50									
51									
52									
53									
54									
55									
56									
57									
58									
59									
60									

	PCR after Ig Region 1	North	2Northeast	3Central	4South	5East
1						
2						
3						3
4						3
5						3
6						3
7						3
8						3
9						3
10						3
11						3
12						3
13						3
14						3
15						3
16						3
17						3
18						3
19						3
20						3
21						3
22						3
23						3
24						3
25						3
26						3
27						2
28						2
29						2
30						2
31						2
32						2
33						2
34						2
35						2
36						2
37						2
38						2
39						2
40						2
41						2
42						2
43						2
44						2
45						2
46						2
47						2
48						2
49						2
50						2
51						2
52						2
53						2
54						2
55						2
56						2
57						2
58						2
59						2
60						2

For peer review only

1		2
2		2
3		2
4		2
5		2
6		2
7		2
8		2
9		2
10		2
11		2
12		5
13		5
14		5
15		5
16		5
17		5
18		5
19		5
20		5
21		5
22		5
23		5
24		5
25		5
26		5
27		5
28		5
29		5
30		5
31		5
32		5
33		5
34		5
35		5
36		5
37		5
38		5
39		5
40		5
41		5
42		5
43		5
44		5
45		5
46		5
47		5
48		5
49		5
50		5
51		5
52		5
53		5
54		5
55		5
56		5
57		5
58		5
59		5
60		5

0

0

0

For peer review only

1	
2	5
3	5
4	5
5	5
6	5
7	5
8	5
9	5
10	5
11	5
12	5
13	5
14	5
15	5
16	5
17	5
18	5
19	5
20	5
21	5
22	5
23	5
24	5
25	5
26	5
27	5
28	5
29	5
30	5
31	5
32	5
33	5
34	5
35	5
36	2
37	2
38	2
39	5
40	5
41	5
42	5
43	5
44	5
45	5
46	5
47	5
48	5
49	5
50	5
51	5
52	5
53	5
54	5
55	5
56	5
57	5
58	5
59	5
60	5



For peer review only

1	
2	5
3	5
4	5
5	5
6	5
7	5
8	5
9	5
10	5
11	5
12	5
13	5
14	5
15	5
16	5
17	5
18	5
19	5
20	5
21	5
22	5
23	5
24	5
25	3
26	3
27	5
28	5
29	5
30	5
31	5
32	5
33	5
34	5
35	5
36	5
37	5
38	5
39	5
40	5
41	5
42	5
43	5
44	5
45	5
46	5
47	5
48	5
49	5
50	5
51	5
52	5
53	5
54	5
55	5
56	5
57	5
58	5
59	5
60	5



0

0

For peer review only

1	5
2	5
3	5
4	5
5	5
6	5
7	5
8	5
9	5
10	5
11	5
12	4
13	4
14	4
15	4
16	4
17	4
18	4
19	4
20	4
21	4
22	4
23	4
24	4
25	4
26	4
27	4
28	4
29	4
30	4
31	4
32	4
33	4
34	4
35	4
36	4
37	4
38	4
39	4
40	4
41	4
42	4
43	4
44	4
45	4
46	4
47	4
48	4
49	4
50	4
51	4
52	4
53	4
54	4
55	4
56	4
57	4
58	3
59	3
60	3

For peer review only

1	3
2	3
3	3
4	3
5	3
6	2
7	2
8	2
9	2
10	2
11	2
12	2
13	2
14	2
15	2
16	2
17	2
18	2
19	2
20	2
21	2
22	2
23	2
24	2
25	2
26	2
27	2
28	2
29	2
30	2
31	2
32	2
33	2
34	2
35	2
36	2
37	2
38	2
39	2
40	2
41	2
42	2
43	2
44	2
45	2
46	2
47	1
48	1
49	1
50	1
51	1
52	1
53	1
54	1
55	1
56	1
57	1
58	1
59	1
60	1

For peer review only

1	1
2	1
3	1
4	1
5	1
6	1
7	2
8	3
9	3
10	3
11	3
12	3
13	3
14	3
15	3
16	3
17	3
18	3
19	3
20	3
21	3
22	3
23	3
24	3
25	2
26	2
27	2
28	2
29	2
30	2
31	2
32	2
33	2
34	2
35	2
36	2
37	2
38	2
39	2
40	2
41	2
42	2
43	2
44	2
45	2
46	2
47	2
48	2
49	2
50	2
51	2
52	2
53	2
54	2
55	2
56	2
57	2
58	2
59	2
60	2

For peer review only

1	2
2	2
3	2
4	2
5	2
6	2
7	2
8	2
9	2
10	2
11	2
12	2
13	2
14	2
15	2
16	2
17	2
18	2
19	2
20	2
21	2
22	2
23	2
24	2
25	2
26	2
27	2
28	2
29	2
30	2
31	2
32	2
33	2
34	2
35	2
36	2
37	2
38	2
39	2
40	4
41	4
42	4
43	4
44	4
45	4
46	4
47	4
48	4
49	4
50	4
51	4
52	4
53	4
54	4
55	4
56	4
57	4
58	4
59	4
60	4

For peer review only

1	4
2	3
3	3
4	3
5	3
6	3
7	3
8	3
9	3
10	3
11	3
12	3
13	3
14	3
15	3
16	3
17	3
18	3
19	3
20	3
21	3
22	3
23	3
24	3
25	3
26	3
27	3
28	3
29	3
30	3
31	3
32	3
33	2
34	2
35	2
36	2
37	2
38	2
39	2
40	2
41	2
42	2
43	2
44	2
45	2
46	2
47	2
48	2
49	2
50	2
51	2
52	2
53	2
54	2
55	4
56	4
57	4
58	4
59	4
60	4

For peer review only

1	4
2	4
3	4
4	4
5	4
6	4
7	4
8	4
9	4
10	4
11	4
12	4
13	4
14	4
15	4
16	4
17	4
18	3
19	3
20	3
21	3
22	3
23	3
24	3
25	3
26	3
27	3
28	3
29	3
30	3
31	3
32	3
33	3
34	3
35	3
36	3
37	2
38	2
39	2
40	2
41	2
42	2
43	2
44	2
45	2
46	2
47	2
48	2
49	2
50	2
51	2
52	2
53	2
54	2
55	2
56	2
57	2
58	2
59	2
60	3

For peer review only

1	3
2	3
3	3
4	3
5	3
6	3
7	3
8	3
9	3
10	3
11	3
12	3
13	3
14	3
15	3
16	3
17	3
18	3
19	3
20	3
21	3
22	3
23	3
24	3
25	3
26	3
27	3
28	3
29	3
30	3
31	3
32	3
33	3
34	3
35	3
36	3
37	3
38	3
39	3
40	3
41	3
42	3
43	3
44	3
45	3
46	2
47	2
48	2
49	2
50	2
51	2
52	2
53	2
54	2
55	2
56	2
57	2
58	2
59	2
60	2



For peer review only

1	2
2	2
3	2
4	2
5	2
6	2
7	2
8	2
9	2
10	3
11	3
12	3
13	3
14	3
15	3
16	3
17	3
18	3
19	3
20	3
21	3
22	3
23	3
24	3
25	3
26	3
27	3
28	3
29	3
30	3
31	3
32	3
33	3
34	3
35	3
36	3
37	3
38	3
39	3
40	3
41	3
42	3
43	3
44	3
45	3
46	3
47	3
48	3
49	3
50	3
51	3
52	3
53	3
54	3
55	3
56	3
57	3
58	5
59	5
60	5








For peer review only

1	5
2	5
3	5
4	5
5	5
6	5
7	5
8	5
9	5
10	5
11	5
12	5
13	5
14	5
15	5
16	5
17	5
18	5
19	5
20	5
21	2
22	2
23	2
24	2
25	2
26	2
27	2
28	2
29	2
30	2
31	2
32	2
33	2
34	2
35	2
36	2
37	2
38	2
39	2
40	2
41	2
42	2
43	2
44	3
45	3
46	3
47	3
48	3
49	3
50	3
51	3
52	3
53	3
54	3
55	3
56	3
57	3
58	3
59	3
60	3

For peer review only



1		3
2		3
3		3
4		3
5		3
6		3
7		3
8		3
9		3
10		3
11		3
12		3
13		3
14		3
15		3
16		3
17		3
18		3
19		3
20		3
21		3
22		3
23		3
24		3
25		3
26		3
27		3
28		3
29		3
30		3
31		3
32		3
33		3
34		3
35		3
36		3
37		3
38		3
39		3
40		3
41		3
42		3
43		1
44		1
45		1
46		1
47		1
48		1
49		1
50		1
51		1
52		1
53		1
54		1
55		1
56		1
57		1
58		1
59		1
60		1

For peer review only

1	1
2	1
3	1
4	1
5	1
6	2
7	2
8	2
9	2
10	2
11	2
12	2
13	2
14	2
15	2
16	2
17	2
18	2
19	2
20	2
21	2
22	2
23	4
24	4
25	4
26	4
27	4
28	4
29	4
30	4
31	4
32	4
33	4
34	4
35	4
36	4
37	4
38	4
39	4
40	4
41	4
42	4
43	4
44	4
45	2
46	2
47	2
48	2
49	2
50	2
51	2
52	2
53	2
54	2
55	2
56	2
57	2
58	2
59	2
60	2

For peer review only

1	2
2	2
3	2
4	2
5	2
6	1
7	1
8	1
9	1
10	1
11	1
12	1
13	1
14	3
15	3
16	3
17	3
18	3
19	3
20	3
21	3
22	3
23	3
24	3
25	3
26	3
27	3
28	3
29	3
30	3
31	3
32	3
33	4
34	4
35	4
36	4
37	4
38	3
39	3
40	3
41	2
42	2
43	2
44	2
45	2
46	2
47	2
48	2
49	2
50	2
51	2
52	2
53	2
54	2
55	4
56	4
57	4
58	4
59	4
60	4

For peer review only

1	
2	1
3	1
4	1
5	1
6	1
7	1
8	1
9	1
10	1
11	1
12	1
13	1
14	1
15	1
16	1
17	1
18	1
19	1
20	2
21	5
22	5
23	5
24	3
25	3
26	3
27	3
28	3
29	3
30	3
31	3
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

For peer review only

	Age	Age stratum	IgM	Region
1				
2				
3		21 20-24 years	1	1
4		22 20-24 years	0	1
5		23 20-24 years	0	1
6		23 20-24 years	0	1
7		25 25-29 years	0	1
8		25 25-29 years	0	1
9		25 25-29 years	0	1
10		26 25-29 years	0	1
11		27 25-29 years	0	1
12		27 25-29 years	0	1
13		28 25-29 years	0	1
14		29 25-29 years	0	1
15		31 30-34 years	0	1
16		31 30-34 years	0	1
17		31 30-34 years	0	1
18		32 30-34 years	0	1
19		32 30-34 years	0	1
20		33 30-34 years	0	1
21		33 30-34 years	0	1
22		33 30-34 years	0	1
23		34 30-34 years	0	1
24		34 30-34 years	0	1
25		34 30-34 years	0	1
26		34 30-34 years	0	1
27		35 35-39 years	0	1
28		36 35-39 years	0	1
29		36 35-39 years	0	1
30		36 35-39 years	0	1
31		36 35-39 years	0	1
32		37 35-39 years	0	1
33		38 35-39 years	0	1
34		39 35-39 years	0	1
35		40 40-44 years	0	1
36		40 40-44 years	0	1
37		40 40-44 years	0	1
38		40 40-44 years	0	1
39		40 40-44 years	0	1
40		40 40-44 years	0	1
41		40 40-44 years	0	1
42		41 40-44 years	0	1
43		41 40-44 years	0	1
44		41 40-44 years	0	1
45		42 40-44 years	0	1
46		42 40-44 years	0	1
47		42 40-44 years	0	1
48		43 40-44 years	0	1
49		43 40-44 years	0	1
50		43 40-44 years	0	1
51		43 40-44 years	0	1
52		45 45-49 years	0	1
53		46 45-49 years	0	1
54		46 45-49 years	0	1
55		47 45-49 years	0	1
56		47 45-49 years	0	1
57		48 45-49 years	0	1
58		49 45-49 years	0	1
59		51 50-54 years	0	1
60		51 50-54 years	0	1

1			
2	51 50-54 years	0	1
3	51 50-54 years	0	1
4	53 50-54 years	0	1
5	53 50-54 years	0	1
6	53 50-54 years	0	1
7	54 50-54 years	0	1
8	55 55-59 years	0	1
9	55 55-59 years	0	1
10	55 55-59 years	0	1
11	56 55-59 years	0	1
12	59 55-59 years	0	1
13	9 5-9 years	0	2
14	11 10-14 years	0	2
15	15 15-19 years	0	2
16	17 15-19 years	0	2
17	17 15-19 years	0	2
18	18 15-19 years	0	2
19	21 20-24 years	0	2
20	21 20-24 years	0	2
21	22 20-24 years	0	2
22	22 20-24 years	0	2
23	22 20-24 years	0	2
24	22 20-24 years	0	2
25	22 20-24 years	0	2
26	22 20-24 years	0	2
27	23 20-24 years	0	2
28	23 20-24 years	0	2
29	23 20-24 years	0	2
30	23 20-24 years	0	2
31	23 20-24 years	0	2
32	23 20-24 years	0	2
33	23 20-24 years	0	2
34	24 20-24 years	0	2
35	24 20-24 years	0	2
36	24 20-24 years	0	2
37	24 20-24 years	0	2
38	24 20-24 years	0	2
39	24 20-24 years	0	2
40	24 20-24 years	0	2
41	24 20-24 years	0	2
42	24 20-24 years	0	2
43	24 20-24 years	0	2
44	24 20-24 years	0	2
45	25 25-29 years	0	2
46	25 25-29 years	0	2
47	25 25-29 years	0	2
48	25 25-29 years	0	2
49	25 25-29 years	0	2
50	25 25-29 years	0	2
51	25 25-29 years	0	2
52	25 25-29 years	0	2
53	25 25-29 years	1	2
54	25 25-29 years	0	2
55	26 25-29 years	0	2
56	26 25-29 years	0	2
57	26 25-29 years	0	2
58	26 25-29 years	0	2
59	26 25-29 years	0	2
60	26 25-29 years	0	2

1			
2	26 25-29 years	0	2
3	26 25-29 years	0	2
4	27 25-29 years	0	2
5	27 25-29 years	0	2
6	27 25-29 years	0	2
7	27 25-29 years	0	2
8	27 25-29 years	0	2
9	27 25-29 years	0	2
10	27 25-29 years	0	2
11	27 25-29 years	0	2
12	27 25-29 years	0	2
13	27 25-29 years	1	2
14	28 25-29 years	0	2
15	28 25-29 years	0	2
16	28 25-29 years	0	2
17	28 25-29 years	0	2
18	28 25-29 years	0	2
19	28 25-29 years	0	2
20	28 25-29 years	0	2
21	28 25-29 years	0	2
22	28 25-29 years	0	2
23	28 25-29 years	0	2
24	28 25-29 years	0	2
25	28 25-29 years	0	2
26	28 25-29 years	0	2
27	28 25-29 years	0	2
28	28 25-29 years	0	2
29	29 25-29 years	0	2
30	29 25-29 years	0	2
31	29 25-29 years	0	2
32	29 25-29 years	1	2
33	29 25-29 years	0	2
34	29 25-29 years	0	2
35	29 25-29 years	0	2
36	29 25-29 years	0	2
37	29 25-29 years	0	2
38	29 25-29 years	0	2
39	29 25-29 years	0	2
40	30 30-34 years	0	2
41	30 30-34 years	0	2
42	30 30-34 years	0	2
43	30 30-34 years	0	2
44	30 30-34 years	0	2
45	30 30-34 years	0	2
46	30 30-34 years	0	2
47	30 30-34 years	0	2
48	30 30-34 years	0	2
49	30 30-34 years	0	2
50	30 30-34 years	0	2
51	30 30-34 years	1	2
52	31 30-34 years	0	2
53	31 30-34 years	0	2
54	31 30-34 years	0	2
55	31 30-34 years	0	2
56	31 30-34 years	0	2
57	31 30-34 years	0	2
58	31 30-34 years	0	2
59	31 30-34 years	0	2
60	31 30-34 years	0	2

1			
2	31 30-34 years	0	2
3	31 30-34 years	0	2
4	31 30-34 years	0	2
5	31 30-34 years	0	2
6	32 30-34 years	0	2
7	32 30-34 years	0	2
8	32 30-34 years	0	2
9	32 30-34 years	0	2
10	32 30-34 years	0	2
11	32 30-34 years	0	2
12	32 30-34 years	0	2
13	32 30-34 years	0	2
14	32 30-34 years	0	2
15	32 30-34 years	0	2
16	33 30-34 years	1	2
17	33 30-34 years	0	2
18	33 30-34 years	0	2
19	33 30-34 years	0	2
20	33 30-34 years	0	2
21	33 30-34 years	0	2
22	33 30-34 years	0	2
23	33 30-34 years	0	2
24	33 30-34 years	0	2
25	33 30-34 years	0	2
26	34 30-34 years	0	2
27	34 30-34 years	0	2
28	34 30-34 years	0	2
29	34 30-34 years	0	2
30	34 30-34 years	0	2
31	35 35-39 years	0	2
32	35 35-39 years	0	2
33	35 35-39 years	0	2
34	35 35-39 years	0	2
35	35 35-39 years	0	2
36	36 35-39 years	0	2
37	36 35-39 years	0	2
38	36 35-39 years	0	2
39	36 35-39 years	0	2
40	36 35-39 years	0	2
41	36 35-39 years	0	2
42	37 35-39 years	0	2
43	37 35-39 years	0	2
44	37 35-39 years	0	2
45	37 35-39 years	0	2
46	37 35-39 years	0	2
47	37 35-39 years	0	2
48	37 35-39 years	0	2
49	37 35-39 years	0	2
50	38 35-39 years	0	2
51	38 35-39 years	0	2
52	38 35-39 years	0	2
53	38 35-39 years	0	2
54	38 35-39 years	0	2
55	38 35-39 years	0	2
56	38 35-39 years	0	2
57	38 35-39 years	0	2
58	38 35-39 years	0	2
59	38 35-39 years	0	2
60	38 35-39 years	0	2
	39 35-39 years	0	2

1			
2	39 35-39 years	0	2
3	39 35-39 years	0	2
4	39 35-39 years	0	2
5	39 35-39 years	0	2
6	39 35-39 years	0	2
7	39 35-39 years	0	2
8	39 35-39 years	0	2
9	39 35-39 years	0	2
10	39 35-39 years	0	2
11	40 40-44 years	0	2
12	40 40-44 years	0	2
13	40 40-44 years	0	2
14	40 40-44 years	0	2
15	40 40-44 years	0	2
16	40 40-44 years	0	2
17	40 40-44 years	0	2
18	40 40-44 years	0	2
19	40 40-44 years	0	2
20	40 40-44 years	0	2
21	40 40-44 years	0	2
22	40 40-44 years	0	2
23	40 40-44 years	0	2
24	40 40-44 years	0	2
25	40 40-44 years	0	2
26	41 40-44 years	0	2
27	41 40-44 years	0	2
28	41 40-44 years	0	2
29	41 40-44 years	0	2
30	41 40-44 years	0	2
31	41 40-44 years	0	2
32	41 40-44 years	0	2
33	41 40-44 years	1	2
34	41 40-44 years	0	2
35	42 40-44 years	0	2
36	42 40-44 years	0	2
37	42 40-44 years	0	2
38	42 40-44 years	0	2
39	42 40-44 years	0	2
40	42 40-44 years	0	2
41	42 40-44 years	0	2
42	42 40-44 years	0	2
43	42 40-44 years	0	2
44	42 40-44 years	0	2
45	42 40-44 years	0	2
46	42 40-44 years	0	2
47	42 40-44 years	0	2
48	43 40-44 years	0	2
49	43 40-44 years	0	2
50	43 40-44 years	0	2
51	43 40-44 years	0	2
52	43 40-44 years	0	2
53	43 40-44 years	0	2
54	43 40-44 years	0	2
55	43 40-44 years	1	2
56	43 40-44 years	0	2
57	43 40-44 years	0	2
58	44 40-44 years	0	2
59	44 40-44 years	0	2
60	44 40-44 years	0	2

1			
2	44 40-44 years	0	2
3	44 40-44 years	0	2
4	44 40-44 years	0	2
5	44 40-44 years	0	2
6	44 40-44 years	0	2
7	44 40-44 years	0	2
8	44 40-44 years	0	2
9	45 45-49 years	0	2
10	45 45-49 years	0	2
11	45 45-49 years	0	2
12	45 45-49 years	0	2
13	45 45-49 years	0	2
14	45 45-49 years	0	2
15	45 45-49 years	0	2
16	45 45-49 years	0	2
17	45 45-49 years	0	2
18	46 45-49 years	0	2
19	46 45-49 years	0	2
20	46 45-49 years	0	2
21	46 45-49 years	0	2
22	46 45-49 years	0	2
23	46 45-49 years	0	2
24	46 45-49 years	0	2
25	47 45-49 years	0	2
26	47 45-49 years	0	2
27	47 45-49 years	0	2
28	47 45-49 years	0	2
29	48 45-49 years	0	2
30	48 45-49 years	0	2
31	48 45-49 years	0	2
32	48 45-49 years	0	2
33	48 45-49 years	0	2
34	48 45-49 years	0	2
35	48 45-49 years	0	2
36	48 45-49 years	0	2
37	48 45-49 years	0	2
38	49 45-49 years	0	2
39	49 45-49 years	0	2
40	49 45-49 years	0	2
41	49 45-49 years	0	2
42	50 50-54 years	0	2
43	50 50-54 years	0	2
44	50 50-54 years	0	2
45	51 50-54 years	0	2
46	51 50-54 years	0	2
47	51 50-54 years	0	2
48	52 50-54 years	0	2
49	52 50-54 years	0	2
50	52 50-54 years	0	2
51	52 50-54 years	0	2
52	53 50-54 years	0	2
53	53 50-54 years	0	2
54	53 50-54 years	0	2
55	53 50-54 years	0	2
56	53 50-54 years	0	2
57	53 50-54 years	1	2
58	54 50-54 years	0	2
59	55 55-59 years	0	2
60	55 55-59 years	0	2

1			
2	56 55-59 years	0	2
3	56 55-59 years	0	2
4	56 55-59 years	0	2
5	56 55-59 years	0	2
6	57 55-59 years	0	2
7	57 55-59 years	0	2
8	58 55-59 years	0	2
9	58 55-59 years	0	2
10	60 60-64 years	0	2
11	60 60-64 years	0	2
12	60 60-64 years	0	2
13	63 60-64 years	0	2
14	66 65-69 years	0	2
15	66 65-69 years	0	2
16		0	2
17		0	2
18		0	2
19		0	2
20		0	2
21		0	2
22		0	2
23		0	2
24	9 5-9 years	0	3
25	10 10-14 years	0	3
26	15 15-19 years	0	3
27	17 15-19 years	0	3
28	18 15-19 years	0	3
29	19 15-19 years	0	3
30	22 20-24 years	0	3
31	22 20-24 years	0	3
32	22 20-24 years	0	3
33	23 20-24 years	0	3
34	23 20-24 years	0	3
35	23 20-24 years	0	3
36	23 20-24 years	0	3
37	23 20-24 years	0	3
38	23 20-24 years	0	3
39	23 20-24 years	0	3
40	23 20-24 years	0	3
41	23 20-24 years	0	3
42	23 20-24 years	0	3
43	24 20-24 years	1	3
44	24 20-24 years	1	3
45	24 20-24 years	0	3
46	24 20-24 years	0	3
47	24 20-24 years	0	3
48	24 20-24 years	0	3
49	24 20-24 years	0	3
50	24 20-24 years	0	3
51	25 25-29 years	0	3
52	25 25-29 years	0	3
53	25 25-29 years	0	3
54	25 25-29 years	0	3
55	25 25-29 years	0	3
56	25 25-29 years	0	3
57	25 25-29 years	0	3
58	25 25-29 years	0	3
59	25 25-29 years	0	3
60	25 25-29 years	0	3

1			
2	25 25-29 years	0	3
3	25 25-29 years	0	3
4	25 25-29 years	0	3
5	25 25-29 years	0	3
6	26 25-29 years	1	3
7	26 25-29 years	0	3
8	26 25-29 years	0	3
9	26 25-29 years	0	3
10	26 25-29 years	0	3
11	26 25-29 years	0	3
12	26 25-29 years	0	3
13	26 25-29 years	0	3
14	26 25-29 years	0	3
15	26 25-29 years	0	3
16	26 25-29 years	0	3
17	26 25-29 years	0	3
18	26 25-29 years	0	3
19	26 25-29 years	0	3
20	26 25-29 years	0	3
21	26 25-29 years	1	3
22	26 25-29 years	0	3
23	26 25-29 years	0	3
24	26 25-29 years	0	3
25	26 25-29 years	0	3
26	26 25-29 years	0	3
27	26 25-29 years	0	3
28	27 25-29 years	0	3
29	27 25-29 years	0	3
30	27 25-29 years	0	3
31	27 25-29 years	0	3
32	27 25-29 years	0	3
33	27 25-29 years	0	3
34	27 25-29 years	0	3
35	27 25-29 years	0	3
36	27 25-29 years	0	3
37	27 25-29 years	0	3
38	27 25-29 years	0	3
39	27 25-29 years	0	3
40	27 25-29 years	0	3
41	27 25-29 years	1	3
42	28 25-29 years	0	3
43	28 25-29 years	0	3
44	28 25-29 years	0	3
45	28 25-29 years	0	3
46	28 25-29 years	0	3
47	28 25-29 years	0	3
48	28 25-29 years	1	3
49	28 25-29 years	0	3
50	29 25-29 years	1	3
51	29 25-29 years	1	3
52	29 25-29 years	0	3
53	29 25-29 years	0	3
54	29 25-29 years	0	3
55	29 25-29 years	1	3
56	29 25-29 years	0	3
57	30 30-34 years	0	3
58	30 30-34 years	0	3
59	31 30-34 years	0	3
60	31 30-34 years	0	3

1			
2	31 30-34 years	0	3
3	31 30-34 years	0	3
4	31 30-34 years	0	3
5	31 30-34 years	0	3
6	32 30-34 years	0	3
7	32 30-34 years	0	3
8	32 30-34 years	0	3
9	32 30-34 years	0	3
10	33 30-34 years	0	3
11	33 30-34 years	1	3
12	33 30-34 years	0	3
13	33 30-34 years	0	3
14	33 30-34 years	0	3
15	33 30-34 years	1	3
16	34 30-34 years	1	3
17	34 30-34 years	0	3
18	34 30-34 years	0	3
19	34 30-34 years	0	3
20	34 30-34 years	0	3
21	34 30-34 years	0	3
22	34 30-34 years	0	3
23	34 30-34 years	0	3
24	34 30-34 years	0	3
25	34 30-34 years	1	3
26	34 30-34 years	0	3
27	35 35-39 years	0	3
28	35 35-39 years	0	3
29	35 35-39 years	0	3
30	36 35-39 years	0	3
31	36 35-39 years	0	3
32	36 35-39 years	0	3
33	36 35-39 years	0	3
34	36 35-39 years	0	3
35	37 35-39 years	0	3
36	37 35-39 years	0	3
37	37 35-39 years	1	3
38	37 35-39 years	0	3
39	37 35-39 years	1	3
40	37 35-39 years	0	3
41	37 35-39 years	1	3
42	37 35-39 years	0	3
43	38 35-39 years	0	3
44	38 35-39 years	0	3
45	38 35-39 years	0	3
46	38 35-39 years	0	3
47	38 35-39 years	0	3
48	39 35-39 years	0	3
49	39 35-39 years	0	3
50	40 40-44 years	1	3
51	40 40-44 years	0	3
52	40 40-44 years	0	3
53	40 40-44 years	0	3
54	40 40-44 years	0	3
55	40 40-44 years	0	3
56	40 40-44 years	1	3
57	41 40-44 years	0	3
58	41 40-44 years	0	3
59	41 40-44 years	0	3
60	41 40-44 years	1	3

1			
2	41 40-44 years	0	3
3	42 40-44 years	0	3
4	42 40-44 years	0	3
5	42 40-44 years	0	3
6	42 40-44 years	0	3
7	42 40-44 years	0	3
8	42 40-44 years	0	3
9	42 40-44 years	0	3
10	42 40-44 years	0	3
11	42 40-44 years	0	3
12	42 40-44 years	0	3
13	42 40-44 years	1	3
14	43 40-44 years	0	3
15	43 40-44 years	0	3
16	43 40-44 years	0	3
17	43 40-44 years	0	3
18	43 40-44 years	0	3
19	43 40-44 years	0	3
20	43 40-44 years	0	3
21	43 40-44 years	0	3
22	44 40-44 years	1	3
23	44 40-44 years	0	3
24	44 40-44 years	0	3
25	44 40-44 years	0	3
26	44 40-44 years	0	3
27	44 40-44 years	0	3
28	44 40-44 years	0	3
29	44 40-44 years	0	3
30	44 40-44 years	0	3
31	44 40-44 years	0	3
32	44 40-44 years	0	3
33	45 45-49 years	0	3
34	45 45-49 years	0	3
35	45 45-49 years	0	3
36	45 45-49 years	0	3
37	45 45-49 years	0	3
38	45 45-49 years	0	3
39	45 45-49 years	0	3
40	45 45-49 years	0	3
41	46 45-49 years	0	3
42	46 45-49 years	0	3
43	46 45-49 years	0	3
44	46 45-49 years	0	3
45	46 45-49 years	0	3
46	47 45-49 years	0	3
47	47 45-49 years	0	3
48	47 45-49 years	0	3
49	48 45-49 years	0	3
50	48 45-49 years	0	3
51	48 45-49 years	0	3
52	48 45-49 years	0	3
53	48 45-49 years	0	3
54	48 45-49 years	0	3
55	49 45-49 years	0	3
56	49 45-49 years	0	3
57	49 45-49 years	0	3
58	50 50-54 years	0	3
59	50 50-54 years	0	3
60	50 50-54 years	0	3

1			
2	50 50-54 years	0	3
3	51 50-54 years	0	3
4	51 50-54 years	0	3
5	51 50-54 years	0	3
6	51 50-54 years	0	3
7			
8	52 50-54 years	0	3
9	52 50-54 years	0	3
10	52 50-54 years	1	3
11	52 50-54 years	0	3
12	53 50-54 years	0	3
13	53 50-54 years	0	3
14	53 50-54 years	0	3
15	53 50-54 years	0	3
16	53 50-54 years	0	3
17	53 50-54 years	0	3
18	53 50-54 years	0	3
19	53 50-54 years	0	3
20	54 50-54 years	0	3
21	54 50-54 years	0	3
22			
23	54 50-54 years	0	3
24	54 50-54 years	0	3
25	55 55-59 years	0	3
26	55 55-59 years	0	3
27	56 55-59 years	0	3
28	56 55-59 years	0	3
29	56 55-59 years	0	3
30	56 55-59 years	0	3
31	56 55-59 years	0	3
32	57 55-59 years	0	3
33	57 55-59 years	0	3
34	57 55-59 years	0	3
35	57 55-59 years	0	3
36	57 55-59 years	0	3
37			
38	58 55-59 years	0	3
39	58 55-59 years	0	3
40	58 55-59 years	0	3
41	59 55-59 years	0	3
42	59 55-59 years	0	3
43	59 55-59 years	1	3
44	59 55-59 years	0	3
45	59 55-59 years	0	3
46	59 55-59 years	0	3
47	60 60-64 years	1	3
48	62 60-64 years	0	3
49	63 60-64 years	1	3
50	63 60-64 years	1	3
51	63 60-64 years	1	3
52	63 60-64 years	1	3
53	66 65-69 years	1	3
54	70 70-74 years	0	3
55	71 70-74 years	1	3
56	72 70-74 years	0	3
57		0	3
58		0	3
59		0	3
60		0	3

1			
2		0	3
3		0	3
4		0	3
5	3 0-4 years	0	4
6	19 15-19 years	0	4
7	19 15-19 years	0	4
8	22 20-24 years	0	4
9	23 20-24 years	0	4
10	23 20-24 years	0	4
11	23 20-24 years	0	4
12	23 20-24 years	0	4
13	24 20-24 years	0	4
14	24 20-24 years	0	4
15	24 20-24 years	0	4
16	24 20-24 years	0	4
17	25 25-29 years	0	4
18	25 25-29 years	0	4
19	25 25-29 years	0	4
20	25 25-29 years	0	4
21	26 25-29 years	0	4
22	26 25-29 years	0	4
23	26 25-29 years	0	4
24	26 25-29 years	0	4
25	26 25-29 years	0	4
26	26 25-29 years	0	4
27	26 25-29 years	0	4
28	27 25-29 years	0	4
29	27 25-29 years	0	4
30	27 25-29 years	0	4
31	27 25-29 years	0	4
32	27 25-29 years	0	4
33	28 25-29 years	0	4
34	28 25-29 years	0	4
35	28 25-29 years	0	4
36	29 25-29 years	0	4
37	29 25-29 years	0	4
38	29 25-29 years	0	4
39	29 25-29 years	0	4
40	30 30-34 years	0	4
41	30 30-34 years	0	4
42	30 30-34 years	0	4
43	30 30-34 years	0	4
44	31 30-34 years	0	4
45	31 30-34 years	0	4
46	31 30-34 years	0	4
47	31 30-34 years	0	4
48	31 30-34 years	0	4
49	31 30-34 years	0	4
50	32 30-34 years	0	4
51	32 30-34 years	0	4
52	32 30-34 years	0	4
53	32 30-34 years	0	4
54	33 30-34 years	0	4
55	34 30-34 years	0	4
56	34 30-34 years	0	4
57	34 30-34 years	0	4
58	35 35-39 years	0	4
59	36 35-39 years	0	4
60	36 35-39 years	0	4

1			
2	36 35-39 years	0	4
3	37 35-39 years	0	4
4	37 35-39 years	0	4
5	37 35-39 years	0	4
6	37 35-39 years	0	4
7	37 35-39 years	0	4
8	37 35-39 years	0	4
9	37 35-39 years	0	4
10	37 35-39 years	0	4
11	39 35-39 years	0	4
12	39 35-39 years	0	4
13	40 40-44 years	0	4
14	40 40-44 years	0	4
15	40 40-44 years	0	4
16	40 40-44 years	0	4
17	41 40-44 years	0	4
18	41 40-44 years	0	4
19	42 40-44 years	0	4
20	42 40-44 years	0	4
21	43 40-44 years	1	4
22	44 40-44 years	0	4
23	45 45-49 years	0	4
24	45 45-49 years	0	4
25	45 45-49 years	0	4
26	45 45-49 years	1	4
27	46 45-49 years	0	4
28	46 45-49 years	0	4
29	46 45-49 years	0	4
30	47 45-49 years	0	4
31	47 45-49 years	0	4
32	47 45-49 years	0	4
33	47 45-49 years	0	4
34	48 45-49 years	0	4
35	48 45-49 years	0	4
36	48 45-49 years	0	4
37	48 45-49 years	0	4
38	49 45-49 years	0	4
39	49 45-49 years	0	4
40	50 50-54 years	0	4
41	51 50-54 years	0	4
42	51 50-54 years	0	4
43	52 50-54 years	0	4
44	52 50-54 years	0	4
45	53 50-54 years	0	4
46	53 50-54 years	0	4
47	54 50-54 years	0	4
48	54 50-54 years	0	4
49	54 50-54 years	0	4
50	54 50-54 years	0	4
51	55 55-59 years	0	4
52	55 55-59 years	0	4
53	55 55-59 years	0	4
54	56 55-59 years	0	4
55	56 55-59 years	0	4
56	56 55-59 years	0	4
57	56 55-59 years	0	4
58	57 55-59 years	0	4
59	60 60-64 years	0	4
60	61 60-64 years	0	4

1			
2	77 75-79 years	0	4
3	80 80-84 years	0	4
4	81 80-84 years	0	4
5		0	4
6		0	4
7		0	4
8		0	4
9		0	4
10		0	4
11	1 0-4 years	0	5
12	2 0-4 years	0	5
13	16 15-19 years	0	5
14	18 15-19 years	0	5
15	19 15-19 years	0	5
16	19 15-19 years	0	5
17	19 15-19 years	0	5
18	20 20-24 years	0	5
19	20 20-24 years	0	5
20	21 20-24 years	0	5
21	21 20-24 years	0	5
22	21 20-24 years	0	5
23	21 20-24 years	0	5
24	21 20-24 years	0	5
25	21 20-24 years	0	5
26	21 20-24 years	0	5
27	21 20-24 years	0	5
28	21 20-24 years	0	5
29	22 20-24 years	0	5
30	22 20-24 years	0	5
31	22 20-24 years	0	5
32	22 20-24 years	0	5
33	23 20-24 years	0	5
34	23 20-24 years	0	5
35	23 20-24 years	0	5
36	24 20-24 years	0	5
37	24 20-24 years	0	5
38	24 20-24 years	0	5
39	24 20-24 years	0	5
40	24 20-24 years	0	5
41	24 20-24 years	0	5
42	24 20-24 years	0	5
43	24 20-24 years	0	5
44	25 25-29 years	1	5
45	25 25-29 years	0	5
46	25 25-29 years	0	5
47	25 25-29 years	0	5
48	25 25-29 years	0	5
49	25 25-29 years	0	5
50	25 25-29 years	0	5
51	25 25-29 years	0	5
52	25 25-29 years	0	5
53	25 25-29 years	0	5
54	25 25-29 years	0	5
55	25 25-29 years	0	5
56	26 25-29 years	0	5
57	26 25-29 years	0	5
58	26 25-29 years	0	5
59	26 25-29 years	0	5
60	26 25-29 years	0	5

For peer review only

1			
2	26 25-29 years	0	5
3	26 25-29 years	1	5
4	26 25-29 years	0	5
5	26 25-29 years	0	5
6	26 25-29 years	0	5
7	26 25-29 years	0	5
8	26 25-29 years	0	5
9	26 25-29 years	0	5
10	26 25-29 years	0	5
11	26 25-29 years	0	5
12	26 25-29 years	0	5
13	26 25-29 years	0	5
14	27 25-29 years	0	5
15	27 25-29 years	0	5
16	28 25-29 years	0	5
17	28 25-29 years	0	5
18	28 25-29 years	0	5
19	28 25-29 years	0	5
20	28 25-29 years	0	5
21	29 25-29 years	0	5
22	29 25-29 years	0	5
23	29 25-29 years	0	5
24	29 25-29 years	0	5
25	29 25-29 years	0	5
26	29 25-29 years	0	5
27	30 30-34 years	0	5
28	30 30-34 years	0	5
29	30 30-34 years	0	5
30	31 30-34 years	1	5
31	31 30-34 years	0	5
32	31 30-34 years	0	5
33	31 30-34 years	0	5
34	31 30-34 years	0	5
35	31 30-34 years	0	5
36	31 30-34 years	0	5
37	32 30-34 years	0	5
38	32 30-34 years	0	5
39	32 30-34 years	0	5
40	32 30-34 years	0	5
41	32 30-34 years	0	5
42	32 30-34 years	0	5
43	32 30-34 years	1	5
44	32 30-34 years	0	5
45	32 30-34 years	0	5
46	32 30-34 years	0	5
47	33 30-34 years	0	5
48	33 30-34 years	0	5
49	33 30-34 years	0	5
50	33 30-34 years	0	5
51	33 30-34 years	0	5
52	34 30-34 years	0	5
53	34 30-34 years	0	5
54	34 30-34 years	0	5
55	34 30-34 years	0	5
56	35 35-39 years	0	5
57	35 35-39 years	0	5
58	35 35-39 years	0	5
59	35 35-39 years	0	5
60	35 35-39 years	0	5

1			
2	35 35-39 years	0	5
3	36 35-39 years	0	5
4	37 35-39 years	0	5
5	38 35-39 years	0	5
6	38 35-39 years	0	5
7	38 35-39 years	0	5
8	38 35-39 years	0	5
9	38 35-39 years	0	5
10	38 35-39 years	0	5
11	38 35-39 years	0	5
12	38 35-39 years	0	5
13	39 35-39 years	1	5
14	39 35-39 years	0	5
15	39 35-39 years	0	5
16	39 35-39 years	0	5
17	39 35-39 years	0	5
18	39 35-39 years	0	5
19	40 40-44 years	0	5
20	41 40-44 years	1	5
21	41 40-44 years	0	5
22	41 40-44 years	0	5
23	41 40-44 years	0	5
24	41 40-44 years	0	5
25	41 40-44 years	0	5
26	41 40-44 years	0	5
27	42 40-44 years	0	5
28	42 40-44 years	0	5
29	43 40-44 years	0	5
30	44 40-44 years	0	5
31	44 40-44 years	0	5
32	44 40-44 years	0	5
33	44 40-44 years	0	5
34	44 40-44 years	0	5
35	44 40-44 years	0	5
36	44 40-44 years	0	5
37	44 40-44 years	0	5
38	45 45-49 years	0	5
39	45 45-49 years	0	5
40	45 45-49 years	0	5
41	45 45-49 years	0	5
42	45 45-49 years	0	5
43	45 45-49 years	0	5
44	45 45-49 years	0	5
45	45 45-49 years	0	5
46	45 45-49 years	0	5
47	46 45-49 years	0	5
48	46 45-49 years	0	5
49	46 45-49 years	0	5
50	46 45-49 years	0	5
51	46 45-49 years	0	5
52	46 45-49 years	0	5
53	46 45-49 years	0	5
54	48 45-49 years	0	5
55	48 45-49 years	0	5
56	48 45-49 years	0	5
57	50 50-54 years	0	5
58	50 50-54 years	0	5
59	51 50-54 years	0	5
60	53 50-54 years	0	5

1			
2	53 50-54 years	0	5
3	53 50-54 years	0	5
4	54 50-54 years	0	5
5	55 55-59 years	0	5
6	55 55-59 years	0	5
7	56 55-59 years	0	5
8	56 55-59 years	0	5
9	56 55-59 years	0	5
10	57 55-59 years	0	5
11	57 55-59 years	0	5
12	59 55-59 years	0	5
13	60 60-64 years	0	5
14	60 60-64 years	0	5
15	67 65-69 years	0	5
16	68 65-69 years	0	5
17	68 65-69 years	0	5
18	70 70-74 years	0	5
19	73 70-74 years	0	5
20	74 70-74 years	0	5
21	76 75-79 years	0	5
22	78 75-79 years	1	5
23	81 80-84 years	0	5
24	83 80-84 years	0	5
25	83 80-84 years	0	5
26	86 85-89 years	0	5
27	95 95-99 years	0	5
28		0	5
29		0	5
30		0	5
31		0	5
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

	Hospital	no. bed	no. staff	region	Healthcare	Patient par	Seroprev	Province	IgM+
1									
2									
3		1	30	193 Central	1	1	42.85714	ปทุมธานี	9
4		2	30	106 Northeast	1	1	0	อุดรธานี	0
5		3	34	130 East	1	0	5.555556	จันทบุรี	4
6		4	30	180 Northeast	0	1	66.66667	อุบลราชธานี	2
7		5	60	196 East	0	1	2.5	ชลบุรี	1
8		6	80	326 Central	0	1	0	นนทบุรี	0
9		7	90	300 East	1	1	5.128205	ชลบุรี	2
10		8	60	280 South	1	0	0	ตรัง	0
11		9	60	218 Central	1	1	0	นครปฐม	0
12		10	135	374 Northeast	1	1	0	นครราชสีมา	0
13		11	30	55 North	1	0	0	เชียงใหม่	0
14		12	30	200 Northeast	1	0	0	ขอนแก่น	0
15		13	60	278 Central	1	0	0	อุทัยธานี	0
16		14	50	160 Northeast	1	1	0	อุดรธานี	0
17		15	114	300 Northeast	1	1	0	อุดรธานี	0
18		16	60	South	1	0	0	สงขลา	0
19		17	30	131 Central	1	1	0	นครปฐม	0
20		18	30	120 Northeast	1	1	0	บุรีรัมย์	0
21		19	10	100 South	0	1	0	ชุมพร	0
22		20	30	130 Central	1	0	0	ชัยนาท	0
23		21	154	520 Central	0	1	0	ลพบุรี	0
24		22	30	189 Central	0	1	20	สุโขทัย	1
25		23	120	450 Northeast	0	1	0	กาฬสินธุ์	0
26		24	60	Central	1	1	0	นนทบุรี	0
27		25	200	626 Central	1	1	5.263158	สมุทรปราการ	1
28		26	60	170 Northeast	1	0	0	ชัยภูมิ	0
29		27	30	120 Northeast	0	1	100	มุกดาหาร	1
30		28	75	250 West	1	0	0	ตาก	0
31		29	10	70 Central	1	0	12.5	พระนครศรีอยุธยา	1
32		30	90	300 Central	1	1	0	อุทัยธานี	0
33		31	30	188 East	1	1	0	จันทบุรี	0
34		32	30	Northeast	1	1	0	อุบลราชธานี	0
35		33	30	120 Central	1	0	30	พระนครศรีอยุธยา	6
36		34	30	72 Central	1	1	0	พิจิตร	0
37		35	30	140 Central	1	0	0	ชัยนาท	0
38		36	60	200 North	1	0	0	แพร่	0
39		37	30	84 Northeast	1	1	0	มหาสารคาม	0
40		38	30	7 South	1	0	0	ชุมพร	0
41		39	36	160 Northeast	1	1	16.66667	นครพนม	3
42		40	90	300 North	1	1	0	เชียงใหม่	0
43		41	100	500 Central	0	1	62.5	เพชรบุรี	5
44		42	30	100 Central	1	1	37.5	สุพรรณบุรี	3
45		43	60	230 South	1	0	66.66667	สุราษฎร์ธานี	2
46		44	30	92 South	0	1	0	นครศรีธรรมราช	0
47		45	30	200 Central	0	1	50	นนทบุรี	1
48		46	30	155 Central	0	1	100	ปทุมธานี	1
49		47	60	200 Northeast	1	1	16.66667	สุรินทร์	2
50		48	60	200 South	1	0	0	กระบี่	0
51		49	60	200 North	1	0	6.25	แม่ฮ่องสอน	1
52		50	120	428 Northeast	0	1	0	อุดรธานี	0
53		51	150	526 East	0	1	0	ชลบุรี	0

1								
2	52	60	300 Central	1	1	16.66667	เพชรบุรี	1
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
13								
14								
15								
16								
17								
18								
19								
20								
21								
22								
23								
24								
25								
26								
27								
28								
29								
30								
31								
32								
33								
34								
35								
36								
37								
38								
39								
40								
41								
42								
43								
44								
45								
46								
47								
48								
49								
50								
51								
52								
53								
54								
55								
56								
57								
58								
59								
60								

For peer review only

	IgG+	IgMorIgG+ N	
1			
2			
3		0	9
4		0	0
5		0	4
6		0	2
7		0	1
8		0	0
9		0	2
10		0	2
11		0	0
12		0	0
13		0	0
14		0	0
15		0	0
16		0	0
17		0	0
18		0	0
19		0	0
20		0	0
21		0	0
22		0	0
23		0	0
24		0	0
25		0	0
26		0	0
27		0	1
28		0	0
29		0	0
30		0	1
31		0	0
32		0	1
33		0	0
34		0	0
35	1	1	1
36	0	0	0
37	0	0	0
38	0	0	0
39	0	0	0
40	0	0	6
41	0	0	0
42	0	0	0
43	0	0	0
44	0	0	0
45	0	0	0
46	0	0	0
47	0	0	3
48	0	0	0
49	1	5	5
50	0	3	3
51	0	2	2
52	0	0	0
53	0	0	1
54	0	1	1
55	0	1	1
56	0	2	2
57	0	0	0
58	0	1	1
59	0	0	0
60	0	0	0

1
2 0 1 6
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

	Hospital	no. bed	no. staff	region	Healthcare	Patient par	Seroprev	Province	IgM+
1									
2									
3	11	30	55	North	1	0	0	เชียงใหม่	0
4	36	60	200	North	1	0	0	แพร่	0
5	40	90	300	North	1	1	0	เชียงใหม่	0
6	49	60	200	North	1	0	6.25	แม่ฮ่องสอน	1
7	2	30	106	Northeast	1	1	0	อุดรธานี	0
8	4	30	180	Northeast	0	1	66.66667	อุบลราชธานี	2
9	10	135	374	Northeast	1	1	0	นครราชสีมา	0
10	12	30	200	Northeast	1	0	0	ขอนแก่น	0
11	14	50	160	Northeast	1	1	0	อุดรธานี	0
12	15	114	300	Northeast	1	1	0	อุดรธานี	0
13	18	30	120	Northeast	1	1	0	บุรีรัมย์	0
14	23	120	450	Northeast	0	1	0	กาฬสินธุ์	0
15	26	60	170	Northeast	1	0	0	ชัยภูมิ	0
16	27	30	120	Northeast	0	1	100	มุกดาหาร	1
17	32	30		Northeast	1	1	0	อุบลราชธานี	0
18	37	30	84	Northeast	1	1	0	มหาสารคาม	0
19	39	36	160	Northeast	1	1	16.66667	นครพนม	3
20	47	60	200	Northeast	1	1	16.66667	สุรินทร์	2
21	50	120	428	Northeast	0	1	0	อุดรธานี	0
22	1	30	193	Central	1	1	42.85714	ปทุมธานี	9
23	6	80	326	Central	0	1	0	นนทบุรี	0
24	9	60	218	Central	1	1	0	นครปฐม	0
25	13	60	278	Central	1	0	0	อุทัยธานี	0
26	17	30	131	Central	1	1	0	นครปฐม	0
27	20	30	130	Central	1	0	0	ชัยนาท	0
28	21	154	520	Central	0	1	0	ลพบุรี	0
29	22	30	189	Central	0	1	20	สุโขทัย	1
30	24	60		Central	1	1	0	นนทบุรี	0
31	25	200	626	Central	1	1	5.263158	สมุทรปราการ	1
32	28	75	250	West	1	0	0	ตาก	0
33	29	10	70	Central	1	0	12.5	พระนครศรีอยุธยา	1
34	30	90	300	Central	1	1	0	อุทัยธานี	0
35	33	30	120	Central	1	0	30	พระนครศรีอยุธยา	6
36	34	30	72	Central	1	1	0	พิจิตร	0
37	35	30	140	Central	1	0	0	ชัยนาท	0
38	41	100	500	Central	0	1	62.5	เพชรบุรี	5
39	42	30	100	Central	1	1	37.5	สุพรรณบุรี	3
40	45	30	200	Central	0	1	50	นนทบุรี	1
41	46	30	155	Central	0	1	100	ปทุมธานี	1
42	52	60	300	Central	1	1	16.66667	เพชรบุรี	1
43	8	60	280	South	1	0	0	ตรัง	0
44	16	60		South	1	0	0	สงขลา	0
45	19	10	100	South	0	1	0	ชุมพร	0
46	38	30	7	South	1	0	0	ชุมพร	0
47	43	60	230	South	1	0	66.66667	สุราษฎร์ธานี	2
48	44	30	92	South	0	1	0	นครศรีธรรมราช	0
49	48	60	200	South	1	0	0	กระบี่	0
50	3	34	130	East	1	0	5.555556	จันทบุรี	4
51	5	60	196	East	0	1	2.5	ชลบุรี	1
52	7	90	300	East	1	1	5.128205	ชลบุรี	2
53	31	30	188	East	1	1	0	จันทบุรี	0

1							
2	51	150	526 East	0	1	0 ชลบุรี	0
3							
4							
5							
6							
7							
8							
9							
10							
11							
12							
13							
14							
15							
16							
17							
18							
19							
20							
21							
22							
23							
24							
25							
26							
27							
28							
29							
30							
31							
32							
33							
34							
35							
36							
37							
38							
39							
40							
41							
42							
43							
44							
45							
46							
47							
48							
49							
50							
51							
52							
53							
54							
55							
56							
57							
58							
59							
60							

For peer review only

	IgG+	IgMorIgG+ N					
1							
2							
3		0	0	18			
4		0	0	20			
5		0	0	7			
6		0	1	16	Region	Seroprev	IgMorIgG+ N
7		0	0	39	North	1.639344	1
8		0	2	3	Northeast	2.973978	8
9		0	0	35	Central	11.88525	29
10		0	0	1	South	1.834862	2
11		0	0	29	East	4.022989	7
12		0	0	36	Total	5.484247	47
13		0	0	19			61
14		0	0	20			269
15		0	0	20			11
16		0	0	20			244
17		0	1	1			109
18		0	0	20			6
19		0	0	15			174
20		0	3	18			2
21		0	2	12			
22		0	0	1			
23		0	9	21			
24		0	0	2			
25		0	0	7			
26		0	0	14			
27		0	0	26			
28		0	0	9			
29		0	0	3			
30		0	1	5			
31		0	0	20			
32		0	1	19			
33		0	0	19			
34		0	1	8			
35		0	0	15			
36		0	6	20			
37		0	0	11			
38		0	0	20			
39		0	5	8			
40		0	3	8			
41		0	1	2			
42		0	1	1			
43		0	1	6			
44		0	0	40			
45		0	0	20			
46		0	0	20			
47		0	5	8			
48		0	3	8			
49		0	1	2			
50		0	1	1			
51		0	1	6			
52		0	0	40			
53		0	0	20			
54		0	0	19			
55		0	2	3			
56		0	0	1			
57		0	0	6			
58		0	4	72			
59		0	1	40			
60		0	2	39			
		0	0	20			

1
2 0 0 3
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

All	%	Samplepop	Allpop	%
9	33.33333	2505118	6350499	39.44758
20	55	15064919	22014248	68.43259
26	50	10053397	18192361	55.26164
14	42.85714	5697112	9493757	60.00904
7	28.57143	2095999	4841806	43.28961
76	46.05263	35416545	60892671	58.16225

For peer review only

No	Hospital	No. bed	No. staff	region	Healthcare	Patient par	Seroprev	Province
1	1	1	30	193 Central	1	1	42.85714	ปทุมธานี
2	46	46	30	155 Central	0	1	100	ปทุมธานี
3	2	2	30	106 Northeast	1	1	0	อุดรธานี
4	14	14	50	160 Northeast	1	1	0	อุดรธานี
5	15	15	114	300 Northeast	1	1	0	อุดรธานี
6	50	50	120	428 Northeast	0	1	0	อุดรธานี
7	3	3	34	130 East	1	0	5.555556	จันทบุรี
8	31	31	30	188 East	1	1	0	จันทบุรี
9	4	4	30	180 Northeast	0	1	66.66667	อุบลราชธานี
10	32	32	30	Northeast	1	1	0	อุบลราชธานี
11	5	5	60	196 East	0	1	2.5	ชลบุรี
12	7	7	90	300 East	1	1	5.128205	ชลบุรี
13	51	51	150	526 East	0	1	0	ชลบุรี
14	6	6	80	326 Central	0	1	0	นนทบุรี
15	24	24	60	Central	1	1	0	นนทบุรี
16	45	45	30	200 Central	0	1	50	นนทบุรี
17	8	8	60	280 South	1	0	0	ตรัง
18	9	9	60	218 Central	1	1	0	นครปฐม
19	17	17	30	131 Central	1	1	0	นครปฐม
20	10	10	135	374 Northeast	1	1	0	นครราชสีมา
21	11	11	30	55 North	1	0	0	เชียงใหม่
22	40	40	90	300 North	1	1	0	เชียงใหม่
23	12	12	30	200 Northeast	1	0	0	ขอนแก่น
24	13	13	60	278 Central	1	0	0	อุทัยธานี
25	30	30	90	300 Central	1	1	0	อุทัยธานี
26	16	16	60	South	1	0	0	สงขลา
27	18	18	30	120 Northeast	1	1	0	บุรีรัมย์
28	19	19	10	100 South	0	1	0	ชุมพร
29	38	38	30	7 South	1	0	0	ชุมพร
30	20	20	30	130 Central	1	0	0	ชัยนาท
31	35	35	30	140 Central	1	0	0	ชัยนาท
32	21	21	154	520 Central	0	1	0	ลพบุรี
33	22	22	30	189 Central	0	1	20	สุโขทัย
34	23	23	120	450 Northeast	0	1	0	กาฬสินธุ์
35	25	25	200	626 Central	1	1	5.263158	สมุทรปราการ
36	26	26	60	170 Northeast	1	0	0	ชัยภูมิ
37	27	27	30	120 Northeast	0	1	100	มุกดาหาร
38	28	28	75	250 West	1	0	0	ตาก
39	29	29	10	70 Central	1	0	12.5	พระนครศรีอยุธยา
40	33	33	30	120 Central	1	0	30	พระนครศรีอยุธยา
41	34	34	30	72 Central	1	1	0	พิจิตร
42	36	36	60	200 North	1	0	0	แพร่
43	37	37	30	84 Northeast	1	1	0	มหาสารคาม
44	39	39	36	160 Northeast	1	1	16.66667	นครพนม
45	41	41	100	500 Central	0	1	62.5	เพชรบุรี
46	52	52	60	300 Central	1	1	16.66667	เพชรบุรี
47	42	42	30	100 Central	1	1	37.5	สุพรรณบุรี
48	43	43	60	230 South	1	0	66.66667	สุราษฎร์ธานี
49	44	44	30	92 South	0	1	0	นครศรีธรรมราช
50	47	47	60	200 Northeast	1	1	16.66667	สุรินทร์
51	48	48	60	200 South	1	0	0	กระบี่

1
2 49 49 60 200 North 1 0 6.25 แม่ฮ่องสอน
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

	IgM+	IgG+	IgMorIlgG+ N	Covidcase	pop	Covidprevalcne
1						
2						
3		9	0	9	21	39 1163604 0.003352
4		1	0	1	1	39 1163604 0.003352
5		0	0	0	39	10 1586646 0.00063
6		0	0	0	29	10 1586646 0.00063
7		0	0	0	36	10 1586646 0.00063
8		0	0	0	1	10 1586646 0.00063
9		4	0	4	72	3 537698 0.000558
10		0	0	0	20	3 537698 0.000558
11		2	0	2	3	15 1878146 0.000799
12		0	0	0	20	15 1878146 0.000799
13		1	0	1	40	134 1558301 0.008599
14		2	0	2	39	134 1558301 0.008599
15		0	0	0	3	134 1558301 0.008599
16		0	0	0	2	158 1265387 0.012486
17		0	0	0	20	158 1265387 0.012486
18		1	0	1	2	158 1265387 0.012486
19		0	0	0	40	7 643164 0.001088
20		0	0	0	7	22 920030 0.002391
21		0	0	0	26	22 920030 0.002391
22		0	0	0	35	19 2648927 0.000717
23		0	0	0	18	41 1779254 0.002304
24		0	0	0	7	41 1779254 0.002304
25		0	0	0	1	6 1802872 0.000333
26		0	0	0	14	1 328618 0.000304
27		0	0	0	15	1 328618 0.000304
28		0	0	0	20	134 1435968 0.009332
29		0	0	0	19	13 1595747 0.000815
30		0	0	0	20	21 511304 0.004107
31		0	0	0	19	21 511304 0.004107
32		0	0	0	9	0 326611 0
33		0	0	0	20	0 326611 0
34		0	0	0	3	2 755556 0.000265
35		1	0	1	5	3 595072 0.000504
36		0	0	0	20	3 983418 0.000305
37		1	0	1	19	143 1344875 0.010633
38		0	0	0	20	3 1137357 0.000264
39		1	0	1	1	4 353174 0.001133
40		0	0	0	19	3 665620 0.000451
41		1	0	1	8	4 820188 0.000488
42		6	0	6	20	4 820188 0.000488
43		0	0	0	11	0 536311 0
44		0	0	0	20	1 441726 0.000226
45		0	0	0	15	1 962665 0.000104
46		3	0	3	18	2 719136 0.000278
47		5	0	5	8	2 485191 0.000412
48		1	0	1	6	2 485191 0.000412
49		3	0	3	8	6 846334 0.000709
50		2	0	2	3	18 1068010 0.001685
51		0	0	0	1	12 1561927 0.000768
52		2	0	2	12	9 1396831 0.000644
53		0	0	0	6	20 476739 0.004195


1
2 1 0 1 16 5 284138 0.00176
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

	Province	Seroprevalence	N	Covidcase	Population	CovidPrev per 100000
1						
2						
3	ปทุมธานี	45.45455	10	22	39 1163604	3.351656
4	อุดรธานี	0	0	105	10 1586646	0.63026
5	จันทบุรี	4.347826	4	92	3 537698	0.557934
6	อุบลราชธานี	8.695652	2	23	15 1878146	0.79866
7	ชลบุรี	3.658537	3	82	134 1558301	8.599109
8	นนทบุรี	4.166667	1	24	158 1265387	12.4863
9	ตรัง	0	0	40	7 643164	1.088369
10	นครปฐม	0	0	33	22 920030	2.391226
11	นครราชสีมา	0	0	35	19 2648927	0.717272
12	เชียงใหม่	0	0	25	41 1779254	2.304337
13	ขอนแก่น	0	0	1	6 1802872	0.332802
14	อุทัยธานี	0	0	29	1 328618	0.304305
15	สงขลา	0	0	20	134 1435968	9.331684
16	บุรีรัมย์	0	0	19	13 1595747	0.814665
17	ชุมพร	0	0	39	21 511304	4.107146
18	ชัยนาท	0	0	29	0 326611	0
19	ลพบุรี	0	0	3	2 755556	0.264706
20	สุโขทัย	20	1	5	3 595072	0.504141
21	กาฬสินธุ์	0	0	20	3 983418	0.305058
22	สมุทรปราการ	5.263158	1	19	143 1344875	10.63296
23	ชัยภูมิ	0	0	20	3 1137357	0.263769
24	มุกดาหาร	100	1	1	4 353174	1.132586
25	ตาก	0	0	19	3 665620	0.450708
26	พระนครศรีอยุธยา	25	7	28	4 820188	0.487693
27	พิจิตร	0	0	11	0 536311	0
28	แพร่	0	0	20	1 441726	0.226385
29	มหาสารคาม	0	0	15	1 962665	0.103878
30	นครพนม	16.66667	3	18	2 719136	0.278112
31	เพชรบุรี	42.85714	6	14	2 485191	0.412209
32	สุพรรณบุรี	37.5	3	8	6 846334	0.70894
33	สุราษฎร์ธานี	66.66667	2	3	18 1068010	1.685377
34	นครศรีธรรมราช	0	0	1	12 1561927	0.768282
35	สุรินทร์	16.66667	2	12	9 1396831	0.644316
36	กระบี่	0	0	6	20 476739	4.195168
37	แม่ฮ่องสอน	6.25	1	16	5 284138	1.759708

857

Spearman's Rho = 0.2225
p=0.1988



Review only

Province	Seroprevalence	N	Covidcase	Population	CovidPrevalence	Region 1	North 2	Northe
เชียงใหม่	0	0	25	41	1779254	2.304337		1
แพร่	0	0	20	1	441726	0.226385		1
แม่ฮ่องสอน	6.25	1	16	5	284138	1.759708		1
อุดรธานี	0	0	105	10	1586646	0.63026		2
อุบลราชธานี	8.695652	2	23	15	1878146	0.79866		2
นครราชสีมา	0	0	35	19	2648927	0.717272		2
ขอนแก่น	0	0	1	6	1802872	0.332802		2
บุรีรัมย์	0	0	19	13	1595747	0.814665		2
กาฬสินธุ์	0	0	20	3	983418	0.305058		2
ชัยภูมิ	0	0	20	3	1137357	0.263769		2
มุกดาหาร	100	1	1	4	353174	1.132586		2
มหาสารคาม	0	0	15	1	962665	0.103878		2
สุรินทร์	16.66667	2	12	9	1396831	0.644316		2
นครพนม	16.66667	3	18	2	719136	0.278112		2
ปทุมธานี	45.45455	10	22	39	1163604	3.351656		3
นนทบุรี	4.166667	1	24	158	1265387	12.4863		3
นครปฐม	0	0	33	22	920030	2.391226		3
อุทัยธานี	0	0	29	1	328618	0.304305		3
ชัยนาท	0	0	29	0	326611	0		3
ลพบุรี	0	0	3	2	755556	0.264706		3
สุโขทัย	20	1	5	3	595072	0.504141		3
สมุทรปราการ	5.263158	1	19	143	1344875	10.63296		3
ตาก	0	0	19	3	665620	0.450708		3
พระนครศรีอยุธยา	25	7	28	4	820188	0.487693		3
พิจิตร	0	0	11	0	536311	0		3
เพชรบุรี	42.85714	6	14	2	485191	0.412209		3
สุพรรณบุรี	37.5	3	8	6	846334	0.70894		3
ตรัง	0	0	40	7	643164	1.088369		4
สงขลา	0	0	20	134	1435968	9.331684		4
ชุมพร	0	0	39	21	511304	4.107146		4
สุราษฎร์ธานี	66.66667	2	3	18	1068010	1.685377		4
นครศรีธรรมราช	0	0	1	12	1561927	0.768282		4
กระบี่	0	0	6	20	476739	4.195168		4
จันทบุรี	4.347826	4	92	3	537698	0.557934		5
ชลบุรี	3.658537	3	82	134	1558301	8.599109		5
					35416545			
			857	864		Spearman's Rho = 0.2225		
						p=0.1988		

1
2 east 3Central 4South 5East
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1		
2	samplepop	
3	north	2505118
4	northeast	15064919
5	central	10053397
6	south	5697112
7	east	2095999
8	Thailand	35416545
9		

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Thailand Population WHO World Population

0-4	3,185,739	88,569
5-9	3,807,943	86,870
10-14	3,953,497	85,970
15-19	4,025,157	84,670
20-24	4,637,316	82,171
25-29	4,746,770	79,272
30-34	4,532,350	76,073
35-39	4,984,910	71,475
40-44	5,144,831	65,877
45-49	5,197,884	60,379
50-54	5,060,459	53,681
55-59	4,516,238	45,484
60-64	3,538,299	37,187
65-69	2,775,155	29,590
70-74	1,919,612	22,092
75-79	1,262,107	15,195
80-84	894,638	9,097
85-89	482,128	4,398
90-94	191,036	1,500
95-99	54,115	400
100 and more	18,969	50
Total	64,929,153	1,000,000

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	4	
Methods				
Study design	4	Present key elements of study design early in the paper	4	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	-	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-5	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-5	
Bias	9	Describe any efforts to address potential sources of bias	-	
Study size	10	Explain how the study size was arrived at	4-5	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5-6
		(c) Explain how missing data were addressed	5-6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	4-5
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-7
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6-7
		(b) Indicate number of participants with missing data for each variable of interest	6-7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	-
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-11
		(b) Report category boundaries when continuous variables were categorized	-
		© If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

COVID-19 seroprevalence among hospital staffs and pre-procedural patients in Thai community hospitals: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046676.R1
Article Type:	Original research
Date Submitted by the Author:	02-Aug-2021
Complete List of Authors:	Nopsopon, Tanawin; Chulalongkorn University Faculty of Medicine Pongpirul, Krit; Chulalongkorn University Faculty of Medicine; Johns Hopkins University Bloomberg School of Public Health Chotirosniramit, Korn; Chulalongkorn University Faculty of Medicine Hiransuthikul, Narin; Chulalongkorn University Faculty of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health, Occupational and environmental medicine, Infectious diseases
Keywords:	Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, COVID-19

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **COVID-19 seroprevalence among hospital staffs and pre-procedural patients in Thai community hospitals: a**
4 **cross-sectional study**

5 Tanawin Nopsopon¹, Krit Pongpirul^{1,2,3}, Korn Chotirosniramit¹, Narin Hiransuthikul¹

7 ¹School of Global Health and Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn
8 University, Bangkok, Thailand

10 ²Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

12 ³Bumrungrad International Hospital, Bangkok, Thailand

14
15 **Correspondence to**

16 Assoc. Prof. Dr. Krit Pongpirul, MD, MPH, PhD

17 Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330,
18 Thailand; doctorkrit@gmail.com

20
21
22 Words: 4,310 words (Text), 247 words (Abstract), 4 tables, 1 figure, 2 supplementary tables

ABSTRACT

Objectives: We aimed to explore the seroprevalence of hospital staff comparing to preprocedural patients in Thai community hospitals to shed light on the situation of COVID-19 infection of frontline healthcare workers in low infection rate countries where mass screening was not readily available.

Design: Cross-sectional study.

Setting: 52 community hospitals in 35 provinces covered all regions of Thailand

Participants: 857 participants consisted of 675 hospital staff and 182 pre-procedural patients

Outcome measure: COVID-19 seroprevalence using a locally developed rapid IgM/IgG test kit

Results: Overall, 5.5% of the participants (47 of 857) had positive immunoglobulin M (IgM), 0.2% (2 of 857) had positive immunoglobulin G (IgG) which both of them also had positive IgM. Hospitals located in the central part of Thailand had the highest IgM seroprevalence (11.9%). Preprocedural patients had a higher rate of positive IgM than the hospital staff (12.1% vs. 3.7%). Participants with present upper respiratory tract symptoms had a higher rate of positive IgM than those without (9.6% vs. 4.5%). Three quarters (80.5%, 690 of 857) of the participants were asymptomatic, of which, 31 had positive IgM (4.5%) which consisted of 20 of 566 healthcare workers (3.5%) and 11 of 124 preprocedural patients (8.9%).

Conclusions: COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals where the nasopharyngeal PCR was not readily available, and the antigen test was prohibited. Antibody testing should be encouraged for mass screening in a limited resource setting, especially in asymptomatic individuals.

Trial registration: Thai Clinical Trials Registry: TCTR20200426002

MeSH Keywords: COVID-19, severe acute respiratory syndrome coronavirus 2, Seroepidemiologic Studies, Hospitals, Thailand

Strengths and limitations of this study

- ▶ This study covered all regions in Thailand and consisted of community hospitals from 35 out of 77 provinces.
- ▶ We used a locally developed IgM/IgG test kit with high internal validation to shed light on the actual COVID-19 situation in areas in which nasopharyngeal PCR testing was not readily available.
- ▶ This study provided a real-life experience to gather crucial information despite restricted resources.
- ▶ We did not have a chance to perform the serological test among the COVID-19 confirmed cases as the mild case had to get quarantined and the moderate and severe ones were referred to a higher level of care, which could affect the seroprevalence.
- ▶ We could not perform multiple serological tests at different time points as doing so was not approved by the ethics committee.

INTRODUCTION

Polymerase chain reaction (PCR) was introduced as a diagnostic test of choice for coronavirus disease 2019 (COVID-19) infection. However, it might not be readily available or affordable in many facilities and could pose an unnecessary risk to the healthcare providers during the specimen collection. Besides, a recent study raised a concern of false-negative results from the nasopharyngeal PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with high pretest probability and encouraged the development of a highly sensitive test.¹

Antibody testing provides additional information for epidemic investigation and control with high sensitivity and simplicity, especially when used along with the nasopharyngeal PCR test. At an early stage of the COVID-19 pandemic, antibody testing was utilized for mass screening to identify and track the missing silent spreaders in Singapore.² Asymptomatic patients are considered to be one of the important sources of COVID-19 transmission,³ with approximately one-fifth transmission rate to close contact individuals.⁴ Additionally, there was a 13% estimated proportion of asymptomatic COVID-19 patients in general and 37% in healthcare providers.⁵

While the nasopharyngeal PCR test was considered gold-standard, there were increasing studies that reported both PCR and antibody test results. In the early phase of pandemic, there was a study in China reported a 2.5% overall COVID-19 seroprevalence in the hospital setting with subgroup analysis of 1.8% in healthcare workers and 3.5% in asymptomatic patients.⁶ Recent meta-analysis reported 8% SARS-CoV-2 seroprevalence in healthcare workers before vaccine initiation.⁷

An early study on the development of SARS-CoV-2 antibodies in symptomatic COVID-19 patients reported that immunoglobulin M (IgM) had the highest value during 20-22 days after onset while immunoglobulin G (IgG) had the highest value during 17-19 days after onset.⁸ More complete information on immunoglobulin development was reported in a recent systematic review that IgM had median seroconversion time between four to 14 days, reached its peak at two to five weeks, then declined to an undetectable level at six weeks post-onset while IgG had median seroconversion time between 12-15 days, reached its peak at three to seven weeks, then diminished after eight weeks after onset.⁹ Since SARS-CoV-2 infectivity was likely to diminish after eight to 13 days post-onset,¹⁰ antibody tests for IgM seroprevalence might not suit for early diagnosis of current COVID-19 cases with infectivity, but would be more appropriate to support the diagnosis of recent COVID-19 infection after two weeks of onset.¹¹

1
2
3 Preferably, utilization of both nasopharyngeal PCR and antibody tests would provide an accurate
4 estimation of the COVID-19 situation in a specific area. However, there were several low- to middle-income
5 countries that could not pay for the cost of nasopharyngeal PCR tests and had to restrict the eligibility for PCR
6 testing to a limited population for the optimization of resource usage. In Thailand, the nasopharyngeal PCR test was
7 offered in suspected individuals with strict criteria during the initial phase of the COVID-19 pandemic. As a more
8 feasible, cheaper, and safer alternative to the nasopharyngeal PCR in a limited resource setting, the antibody test is
9 not only useful for an epidemiological investigation but could also be used for mass screening of potential silent
10 spreaders—asymptomatic COVID-19 individuals.²
11
12
13
14
15
16
17
18

19 Hospital is one of the best venues for getting and spreading pathogens. There are two types of people in the
20 hospital who potentially are silent spreaders and need antibody testing: (1) healthcare workers who have a relatively
21 higher risk of infection than laypersons, and (2) asymptomatic patients who need procedural treatment or operation
22 but do not meet the criteria for nasopharyngeal PCR testing.
23
24
25
26

27 **METHODS**

28 **Study Population**

29
30 From 8th April to 26th June 2020, hospital staff and patients who needed procedural treatment or operation visiting
31 the hospital during the recruiting period and did not meet the national nasopharyngeal PCR testing criteria in 244
32 hospitals (215 community hospitals and 29 general hospitals) from all regions of Thailand were recruited for
33 antibody testing in their community hospital. Hospitals included in the study came from a national survey about
34 willingness to use antibody testing for COVID-19 screening. Of 215 community hospitals, data from 52 hospitals
35 (24.2%) in 35 provinces from all regions which could be considered representative of community hospitals across
36 Thailand were readily available for the analysis performed on June 29, 2020. Participants with active symptoms
37 meeting national criteria for nasopharyngeal PCR testing were quarantined and excluded. Participants were asked to
38 answer a questionnaire about risk history for COVID-19, recent symptoms within the past two weeks, and previous
39 nasopharyngeal PCR test results if available.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

National criteria for nasopharyngeal PCR testing for COVID-19

National criteria for nasopharyngeal PCR testing for COVID-19 for symptomatic layperson during the study period included fever with one of the upper respiratory infection symptoms (cough, rhinitis, sore throat, anosmia, tachypnea, or dyspnea) and one of risk history (history of travel to a high-risk area, an occupation involving tourists, crowded place, or contact with many people, history of going to crowded place in the community, or history of close contact confirmed COVID-19 case) within 14 days before the onset of symptoms. For symptomatic healthcare workers, the criteria were less strict. Either fever or one of the upper respiratory infection symptoms was sufficient for PCR testing. During recruiting period, there was almost impossible for an asymptomatic person to get PCR tested.

Antibody testing

Baiya Rapid COVID-19 IgG/IgM test kit (Baiya Phytopharm, Thailand) which reports the presence of immunoglobulin M (IgM) and immunoglobulin G (IgG) qualitatively using lateral flow immunoassay technique and receptor-binding protein of spike protein of SARS-CoV-2 for antigen, was used in this study free of charge. The internal validation of the test kit using the serum of 51 nasopharyngeal PCR confirmed COVID-19 cases and 150 controls showed sensitivity 94.1% (48 of 51) and specificity 98.0% (147 of 150) for IgM or IgG antibody. Of 51 PCR confirmed COVID-19 cases, 56.9% (29 of 51) were IgM+ IgG-, 37.3% (19 of 51) were IgM+ IgG+, 5.9% (3 of 51) were IgM-IgG-. No IgM- IgG+ was detected in 51 PCR confirmed COVID-19 cases from interval validation. Participants with positive IgM were encouraged to have a nasopharyngeal PCR test if available. There was no hospital or center readily available for neutralizing antibody testing during the study period.

Age-adjusted seroprevalence

PCR confirmed COVID-19 cases were obtained from the Thailand government report on June 30, 2020. Seroprevalence data were presented as unadjusted seroprevalence and compared with direct age-adjusted seroprevalence using combined participating population, Thailand population, and world population provided by the world health organization (WHO) for 2000-2025 population.

Statistical analysis

Categorical data were presented with counts and percentages while continuous data were provided with median and

interquartile ranges. The 95% confidence interval (CI) of the seroprevalence was calculated by Wilson's method using binomial probabilities. Correlation between seroprevalence and PCR confirmed COVID-19 prevalence was tested using Spearman's correlation. Missing data were excluded. A two-tailed $p < 0.05$ was considered statistically significant. All data were analyzed using Stata 16.1 (College Station, TX).

Patient and public involvement statement

The research question and outcome measure were developed from both patient and public involvement. For patient involvement, visiting a hospital must not harm patients; however, the unknown status of COVID-19 infection in the pandemic period led to a doubtful situation of no harm. For public involvement, the national policy about COVID-19 test at the study period made unstable situation among the public, a national survey was conducted to identify the situation in the community and general hospitals to find places that should be the priority for this study to provide more confidence situation for hospital visiting and working. Patients and hospital staff who participated in this study had a report for their serology status, and the results of this study would be disseminated not only to participants but also to the public via an online channel to provide evidence of the actual situation.

RESULTS

Community hospital demographic

Overall, 52 community hospitals from 46.1% of provinces in Thailand (35 of 76) which consisted of 58.2% of national population (35,416,545 of 60,892,671) participated in this study. Participation rates varied across regions—Northeastern (55%), Central (50.0%), Southern (42.9%), Northern (33.3%), and Eastern (28.6%) (supplementary table E1).

Participant demographic

From 52 community hospitals, 857 participants which consisted of 675 hospital staff and 182 pre-procedural patients were included in the study. Their median age was 37 years (interquartile range 27–45), 74.7% were female, 98.8% were Thai, and 80.5% were asymptomatic. The most common symptoms were cough (9.7%), rhinitis (7.5%), sore throat (6.4%), fever (5.7%), and dyspnea (3.5%). History of travel to the high-risk area was 6.0%, history of close contact to the confirmed COVID-19 case was 15.4%, and 14.5% had nasopharyngeal PCR negative (table 1). Forty-seven participants (5.5%, 95% CI 4.1 to 7.2) had IgM antibodies against SARS-CoV-2 whereas the IgG antibody was found in two participants (0.2%, 95% CI 0.1 to 0.8). Participants from the Central region of Thailand

had the highest IgM seroprevalence (11.9%, 95% CI 8.4 to 16.5), while the Northern region had the lowest seroprevalence (1.6%, 95% CI 0.3 to 8.7) (figure 1).

Table 1 Demographic details of participants

	All Participants N (%)	Hospital Staff n (%)	Pre-procedural Patients n (%)
Total	857	675	182
Median age, years (25th–75th percentile)	37 (27–45)	36.5 (28–45)	37 (25–53)
Male	207 (24.1%)	145 (21.5%)	62 (34.1%)
Female	640 (74.7%)	521 (77.2%)	119 (65.4%)
Unspecified	10 (1.2%)	9 (1.3%)	1 (0.5%)
Thai	847 (98.8%)	671 (99.4%)	176 (96.7%)
Non-Thai	10 (1.2%)	4 (0.6%)	6 (3.3%)
Region			
North	61 (7.1%)	59 (8.8%)	2 (1.1%)
Northeast	269 (31.4%)	220 (32.6%)	49 (26.9%)
Central	244 (28.5%)	183 (27.1%)	61 (33.5%)
South	109 (12.7%)	88 (13.0%)	21 (11.6%)
East	174 (20.3%)	125 (18.5%)	49 (26.9%)
History of travel to high risk area			
Yes	51 (6.0%)	20 (3.0%)	31 (17.0%)
No	806 (94.0%)	655 (97.0%)	151 (83.0%)
History of close contact confirmed case			
Yes	132 (15.4%)	121 (17.9%)	11 (6.0%)
No	725 (84.6%)	554 (82.1%)	171 (94.0%)
Asymptomatic	690 (80.5%)	566 (83.9%)	124 (68.1%)
Symptomatic	167 (19.5%)	109 (16.1%)	58 (31.9%)
Fever	49 (5.7%)	17 (2.5%)	32 (17.6%)
Cough	83 (9.7%)	52 (7.7%)	31 (17.0%)
Rhinitis	64 (7.5%)	47 (7.0%)	17 (9.3%)
Sore throat	55 (6.4%)	37 (5.5%)	18 (9.9%)
Dyspnea	30 (3.5%)	3 (0.4%)	27 (14.8%)
Previous nasopharyngeal PCR status			
Negative	124 (14.5%)	77 (11.4%)	47 (25.8%)
Never tested	733 (85.5%)	598 (88.6%)	135 (74.2%)

Data were presented in counts and percentages unless otherwise specified.
PCR, polymerase chain reaction.

Age-adjusted immunoglobulin M (IgM) seroprevalence

Age-adjusted IgM seroprevalence with combined participating population showed almost similar results with unadjusted IgM seroprevalence. However, age-adjusted seroprevalence using Thailand population showed increasing seropositive rate in Thailand from 5.5% to 6.3%, Central region from 11.9% to 15.3%, and Northern region from 1.6% to 1.8%, while decreasing seroprevalence in Northeastern region from 3.0% to 1.6%, Eastern region from 4.0% to 2.8%, and Southern region from 1.8% to 1.5%. Adjusted with the world standard population from the World Health Organization (WHO 2000-2025) showed decreasing trends of seroprevalence both overall and in most regions (table 2).

Table 2 Unadjusted and age-adjusted immunoglobulin M seroprevalence in community hospitals across geographical regions of Thailand

Regions	Unadjusted IgM Seroprevalence	Age-adjusted IgM Seroprevalence with Combined Participating Population	Age-adjusted IgM Seroprevalence with Thailand Population	Age-adjusted IgM Seroprevalence with World Standard Population
Thailand*	5.5%	NA	6.3%	5.1%
Northern	1.6%	2.2%	1.8%	2.1%
Northeastern	3.0%	3.0%	1.6%	1.5%
Central*	11.9%	11.9%	15.3%	12.2%
Southern	1.8%	2.4%	1.5%	1.2%
Eastern	4.0%	3.9%	2.8%	2.6%

* Not include Bangkok which has no community hospital.
IgM, immunoglobulin M; NA, not available; WHO, World Health Organization.

Participant characteristics and seroprevalence

Pre-procedural patients had an unexpectedly higher proportion of positive IgM than the hospital staff (12.1% vs. 3.7%), especially patients in the Central region of Thailand (27.9%, 95% CI 18.2 to 40.2) while patients in the Northern and Southern regions showed zero seroprevalences. Also, hospital staff in the Central region had the highest seroprevalence (6.6%, 95% CI 3.8 to 11.1) while those in the Northern region had the lowest (1.7%, 95% CI 0.3 to 9.0). Overall, the seropositive prevalence was not different between males and females (5.8% vs. 5.5%). Paradoxically, the seroprevalences were higher in participants without a history of travel to a high-risk area (5.6% vs. 3.9%) and those without a history of close contact to confirmed COVID-19 case (5.7% vs. 4.5%) than their counterparts. The same paradox also applied to pre-procedural patients. Patients without travel history were likely to have an antibody for SARS-CoV-2 (13.9% vs. 3.2%) and patients without close contact to the case also had more chance to develop an antibody (12.3% vs. 9.1%). However, healthcare workers with travel history had slightly more chance to develop IgM (5.0% vs. 3.7%) and with close contact history (4.1% vs. 3.6%). In general, participants with upper respiratory tract symptoms had a higher chance of being seropositive (9.6% vs. 4.5%), of which dyspnea had the highest (30.0%, 95% CI 16.7 to 47.9). Likewise, pre-procedural patients with dyspnea had the most IgM positive (29.6%, 95% CI 15.9 to 48.5) and healthcare workers with dyspnea (33.3%, 95% CI 6.1 to 79.2). Of 690 participants without present upper respiratory tract symptoms, 31 had IgM positive for COVID-19 (4.5%, 95% CI 3.2 to 6.3) which consisted of 20 of 566 healthcare workers (3.5%, 95% CI 2.3 to 5.4) and 11 of 124 patients (8.9%, 95% CI

5.0 to 15.2). History of negative nasopharyngeal PCR was associated with a surprisingly higher chance of seropositive than those with no PCR test result (6.5% vs. 5.3%) (Table 3). Unfortunately, none of the participants with positive IgM had opportunities for nasopharyngeal PCR testing.

Table 3 Demographic characteristics and seroprevalence in hospital staff and pre-procedural patients

	All Participants		Hospital Staff		Pre-procedural Patients	
	N	IgM+	n	IgM+	n	IgM+
Total	857	47 (5.5%)	675	25 (3.7%)	182	22 (12.1%)
Median age, years (25th–75th percentile)	37 (27–45)		36.5 (28–45)		37 (25–53)	
Male	207 (24.1%)	12 (5.8%)	145(21.5%)	6 (4.1%)	62 (34.1%)	6 (9.7%)
Female	640 (74.7%)	35 (5.5%)	521(77.2%)	19 (3.6%)	119 (65.4%)	16 (13.4%)
Unspecified	10 (1.2%)	0 (0.0%)	9 (1.3%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
Thai	847	47 (5.5%)	671	25 (3.7%)	176	22 (12.5%)
Non-Thai	10	0(0.0%)	4	0 (0.0%)	6	0 (0.0%)
Region						
North	61	1 (1.6%)	59	1 (1.7%)	2	0 (0.0%)
Northeast	269	8 (3.0%)	220	4(1.8%)	49	4 (8.2%)
Central	244	29 (11.9%)	183	12 (6.6%)	61	17 (27.9%)
South	109	2 (1.8%)	88	2 (2.3%)	21	0 (0.0%)
East	174	7 (4.0%)	125	6 (4.8%)	49	1 (2.0%)
History of travel to a high-risk area						
Yes	51	2 (3.9%)	20	1 (5.0%)	31	1 (3.2%)
No	806	45 (5.6%)	655	24 (3.7%)	151	21 (13.9%)
History of close contact confirmed case						
Yes	132	6(4.5%)	121	5(4.1%)	11	1 (9.1%)
No	725	41 (5.7%)	554	20 (3.6%)	171	21 (12.3%)
Asymptomatic	690	31 (4.5%)	566	20 (3.5%)	124	11 (8.9%)
Symptomatic	167	16 (9.6%)	109	5 (4.6%)	58	11 (19.0%)
Fever	49	7 (14.3%)	17	0 (0.0%)	32	7 (21.9%)
Cough	83	8 (9.6%)	52	1 (1.9%)	31	7 (22.6%)
Rhinitis	64	7 (10.9%)	47	2 (4.3%)	17	5 (29.4%)
Sore throat	55	8 (14.5%)	37	3 (8.1%)	18	5 (27.8%)
Dyspnea	30	9 (30.0%)	3	1 (33.3%)	27	8 (29.6%)
Previous nasopharyngeal PCR status						
Negative	124	8 (6.5%)	77	1 (1.3%)	47	7 (14.9%)
Never tested	733	39 (5.3%)	598	24 (4.0%)	135	15 (11.1%)

Data were presented in counts and percentages unless otherwise specified.

IgM+, immunoglobulin M positive; NA, not available; PCR, polymerase chain reaction.

COVID-19 prevalence and immunoglobulin M seroprevalence

PCR confirmed COVID-19 case and population data were acquired for participating provinces. Overall, COVID-19 prevalence was 2.44 cases per 100,000 population. Participating provinces in the Eastern region had the highest prevalence of COVID-19 (6.54 cases per 100,000 population) while provinces in the northeastern had the lowest prevalence (supplemental table E2). There was no correlation between IgM seroprevalence, and PCR confirmed COVID-19 prevalence ($p=0.199$).

Characteristics of immunoglobulin G seropositive participants

IgG was detected in two participants (0.2%, 95% CI 0.1 to 0.8) who also had a positive IgM antibody. In other words, we did not find any participants with isolated positive IgG. Participant A was a Thai female healthcare worker who worked in a community hospital in the Central region of Thailand. She had a sore throat but had no history of travel to a high-risk area or close contact to a confirmed COVID-19 case and did not have a nasopharyngeal PCR test before. Participant B was a Thai female preprocedural patient who visited another community hospital in the Central region. She had no symptoms, no history of travel to a high-risk area, or close contact to confirmed the COVID-19 case. Participant B had a previously negative nasopharyngeal PCR result (table 4).

Table 4 Characteristics of Participants who Developed Immunoglobulin G Antibody

	Age Range, years	Gender	Ethnicity	Region	Occupation	History of travel to a high-risk area	History of contact to a confirmed case	Symptoms	Previous PCR status
Participant A	56-60	Female	Thai	Central	HCW	No	No	Sore throat	Never tested
Participant B	41-45	Female	Thai	Central	Patient	No	No	No	Negative

HCW, healthcare worker; PCR, polymerase chain reaction; Age range was used for participant's privacy and confidentiality.

DISCUSSION

During an early phase of the pandemic in Thailand, which had approximately 61 million inhabitants located in the South-East Asia region, there were 5.5% overall estimated IgM and 0.2% overall IgG seroprevalence in community hospital staffs and pre-procedural patients. Overall IgM seroprevalence was highest in the community hospitals located in the central region of Thailand. Pre-procedural patients showed a higher estimated IgM seroprevalence than the healthcare workers (12.1% vs. 3.7%). Among asymptomatic participants accounted for approximately 80% of participants, the overall estimated IgM seroprevalence was 4.5% which could be subcategorized to 3.5% in healthcare workers and 8.9% in pre-procedural patients. Additionally, participants with present upper respiratory tract symptoms had a higher rate of positive IgM at 9.6%.

COVID-19 seroprevalence in asymptomatic staff and patients in Thai community hospitals was higher than in hospitals in China (4.5% vs. 2.5%).⁶ Seroprevalence in asymptomatic hospital staff in Thailand was also higher than hospitals in China (3.5% vs. 1.8%),⁶ but less than a tertiary hospital in Belgium (3.5% vs. 6.4%).¹² Moreover, seroprevalence in asymptomatic hospital staff in Thailand community hospital was higher than asymptomatic

1
2
3 hospital staffs in a Thai provincial hospital (3.5% vs 0.7%),¹³ but was less than asymptomatic frontline
4
5 firefighters/paramedics of US fire department (3.5% vs 7.7%).¹⁴ Asymptomatic patients in Thailand seemed to have
6
7 higher seroprevalence than in China (8.9% vs.3.5%).⁶ Unlike China and Belgium where the seroprevalences were
8
9 mostly from positive IgG, our study revealed mostly positive IgM. The possible explanation would be different
10
11 study periods among studies that represented the different stages of epidemic in the regions. Comparison with a
12
13 Belgium hospital should be interpreted with caution due to the unknown nasopharyngeal PCR status of Belgium
14
15 subjects.

16
17 Most seropositive participants in this study had positive IgM only while only a few had both positive IgM
18
19 and IgG. We conjecture three possible explanations which might relate to the dominance of IgM positive results.
20
21 First, the relation of antibody testing timepoint and the onset of COVID-19 might play a significant contribution.¹⁵
22
23 Although both IgM and IgG could develop to be detectable in some patients during the first-week post-onset,¹⁶
24
25 approximately 70% of symptomatic patients developed IgM to detectable level during the second week after onset
26
27 and raised to 90% of total antibody test positive by days 11-24 post-onset.¹⁷ Regards the immunoglobulin level,
28
29 COVID-19 confirmed cases usually had higher IgM levels than IgG during the first two weeks after onset with a
30
31 reversal afterward.¹⁸ The study period was an early stage of the pandemic in Thailand, thus the participants with
32
33 recent COVID-19 infection might not develop detectable IgG yet, thus lead to a false-negative result of the IgG
34
35 test.¹⁹ Second, there was heterogeneity regards antibody development since some COVID-19 patients might have
36
37 impregnable innate immunity and recovered from the disease without developing any antibody.²⁰ Third, the
38
39 exclusion criteria of our observational study excluded all confirmed COVID-19 cases who had a higher chance of
40
41 developed IgG.

42
43 Since the study was based on a hospital setting, the IgM seroprevalence in the study might be an
44
45 overestimation of the general population due to the higher risk of COVID-19 infection in hospitals,²¹ especially in
46
47 the Central region of Thailand where the high population density might associate with the increasing transmission.²²
48
49 ²³ On the other hand, the antibody test for IgM might underestimate the true prevalence of COVID-19 infection in
50
51 the hospital setting, particularly those who were in the infectious stage since the IgM seroprevalence was more
52
53 effective to support the diagnosis of recent COVID-19 infection after two weeks of onset,¹¹ while the infectivity was
54
55 likely to plummet during the first and second week of onset.¹⁰
56
57
58
59
60

1
2
3 There was a very high proportion of participants who had been contacted with COVID-19 confirmed cases.
4
5 This situation was not unexpected because the participants who had contact with the confirmed case might seek
6
7 medical care and nasopharyngeal PCR test, but they were not eligible for the PCR test due to national policy during
8
9 the study period required patients to be both symptomatic and had a high risk of exposure to COVID-19 to get
10
11 tested. However, people with a history of close contact to confirmed COVID-19 cases or travel to a high-risk area
12
13 turned out to have a low COVID-19 seroprevalence in our study. One possible explanation could be the successful
14
15 implementation of the national nasopharyngeal PCR-based screening policy, low barrier to medical care under the
16
17 Universal Coverage scheme as well as disease awareness and health literacy of the Thais. People with those
18
19 predefined risks might have already sought medical attention; several cases might have been identified with the PCR
20
21 test and were either quarantined or sent to proper care. The remaining eligible individuals might be dominated by
22
23 those without the predefined risks.
24

25 To prevent nosocomial spread in a community hospital or primary hospital setting, hospital staff should be
26
27 tested for COVID-19 before working their routine and should repeat the test at a specified period. Antibody testing
28
29 was less uncomfortable than nasopharyngeal PCR testing which might lead to more compliance when hospital staff
30
31 was planned to get multiple tests. False-negative could occur in any test. High sensitivity testing was encouraged for
32
33 high-risk populations including hospital staff to reduce false negatives.¹ Negative result on nasopharyngeal PCR
34
35 with negative antibody test or IgG positive only might be acceptable for hospital staff starting the work when such
36
37 highly sensitive test was not completely developed. To help prevent community spread in an aspect of a community
38
39 hospital setting, patients who visited the hospital with any chief complain should be tested with rapid antibody
40
41 testing to screen some potential spreader and prevent them from returning to the community during spreadable
42
43 period especially when nasopharyngeal PCR testing was not readily available in a remote area.
44

45 Serological testing provides some crucial epidemiological information and would have been more effective
46
47 when combined with other diagnostic tests such as nasopharyngeal PCR or rapid antigenic tests. However, there was
48
49 a unique situation in Thailand during the study period in which the eligibility criteria for nasopharyngeal swabs for
50
51 PCR test were very strict and those who should have been tested mostly did not meet the strict criteria. Moreover,
52
53 the rapid antigenic tests were not approved in Thailand until July 2021. While all participants with positive results
54
55 from the free-of-charge rapid IgM/IgG test provided in this study were encouraged to get nasopharyngeal PCR
56
57

1
2
3 testing, a majority of community hospitals still did not have access to the PCR testing because of both financial and
4 non-financial reasons. The recommendation for nasopharyngeal PCR testing after positive rapid IgM/IgG test was
5 not fully complied so we did not have information about the participants with positive IgM. However, with the
6 immunoglobulin status and PCR results, we can shape the situation more accurately for both individual and regional
7 views. Hopefully, with this and other vigorous and dedicated studies on antibody status around the globe, serology
8 testing would provide useful information for pandemic control.
9
10
11
12
13

14
15 Given the fact that IgM represents a recent infection while IgG is suggestive of past infection, excluding
16 COVID-19 confirmed cases who had a higher chance of developing IgG during the study period would
17 underestimate the actual IgG seroprevalence and underestimate the actual proportion of seropositive participants
18 who had previous nasopharyngeal PCR testing. While this might be considered a limitation of our study as
19 compared to other studies that did not exclude COVID-19 confirmed cases, our observation reflected a real picture
20 of seroprevalence in a country with low COVID-19 incidence and mortality. We did not have a chance to perform
21 the serological test among the COVID-19 confirmed cases as the mild case had to get quarantined and the moderate
22 and severe ones were referred to a higher level of care. Also, we could not perform multiple serological tests at
23 different time points as doing so was not approved by the ethics committee.
24
25
26
27
28
29
30
31
32

33 Only 2 out of 47 IgM-positive participants also had IgG-positive and none of the IgM-positive participants
34 got subsequent nasopharyngeal PCR test after IgM-positive status. There was a possibility that IgM positive might
35 be false positive. However, the false-positive rate for IgM or IgG was 2% according to internal validation of the test
36 kit while IgM positive seroprevalence was 5.5%. While the false positive of IgM might occur due to imperfection of
37 test kit and no confirmation with PCR test after positive antibody against COVID-19 which might lead to
38 overestimation of actual IgM seroprevalence, this limitation shaped the real-world situation in an early phase of
39 pandemic awareness in a community hospital setting where more advanced test methods were not readily available.
40
41
42
43
44
45
46

47 **CONCLUSIONS**

48
49 COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals
50 where the nasopharyngeal PCR was not readily available, and the antigen test was prohibited. Antibody testing
51 should be encouraged for mass screening in a limited resource setting, especially in asymptomatic individuals.
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgments** We thank Baiya Phytopharm, Thailand for supporting the Baiya Rapid COVID-19 IgG/IgM test
4 kit. The company did not involve in the data analysis, interpretation, and manuscript preparation.

5
6
7 **Contributors** TN conceptualized the study, design the methodology, administrated the project, contributed to data
8 curation and clinical investigation, validate the data, performed formal analysis and provided software, visualized
9 the data, and wrote the original draft of the manuscript. KP conceptualized the study, design the methodology,
10 administrated the project, contributed to data curation and clinical investigation, validate the data, performed formal
11 analysis and provided software, provided resources for the study, supervised the study, and wrote the original draft
12 of the manuscript. KC contributed to data curation and clinical investigation, and validate the data. NH
13 conceptualized the study, design the methodology, administrated the project, provided resources for the study, and
14 supervised the study. All authors reviewed, edited the final manuscript, agreed to be held accountable for all aspects
15 of the work related to its accuracy and integrity.

16
17
18 **Funding** The authors have not declared a specific grant for this research from any funding agency in the public,
19 commercial or not-for-profit sectors.

20
21
22 **Competing Interests** None declared.

23
24
25 **Patient and public involvement** Patient and/or the public were involved in the design, or conduct, or reporting, or
26 dissemination plans of this research. Refer to the Methods section for further details.

27
28
29 **Patient consent for publication** Not required.

30
31
32 **Ethics approval** Ethics approval was obtained from the Institutional Review Board of Chulalongkorn University
33 (IRB No.236/63), Ethics Committee of National Cancer Institute Thailand (EC No.015/2563), Research Ethics
34 Committee of Nan Hospital (REC No.063/2563), Ethics Committee of Chaophraya Yommarat Hospital (YM
35 No.013/2563), Institutional Review Board of Songkhla Hospital (IRB No.2020-Md-J3-04001), Ethics Committee of
36 Lamphang Hospital (EC No.26/63), Ethics Committee of Sikhio Hospital (SK No.2020/001), Ethics Committee of
37 Samut Sakhon Hospital, Research Ethics Committee of Prapokklao Hospital (CTIREC No.030/63), Institutional
38 Review Board of Burapha University (HS No.027/2563), Ethics Committee of Srinakharinwirot University
39 (SWUEC No. 119/2563F), Institutional Review Board of Phaholpolpayuhasena Hospital (IRB No.2020-04),
40 Institutional Review Board of Samitivej Sukhumvit Hospital (IRB No.001/2563), Research Ethics Committee of
41 Pattani Provincial Public Health Office (RECPTN No.015/63), Institutional Review Board of Bangplee Hospital
42 (IRB No.1/2563), Institutional Review Board of Chonburi Hospital (IRB No.08/2563), Institutional Review Board
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of Surin Hospital (IRB No.15/2563), Institutional Review Board of Child and Adolescent Mental Health
4
5 Rajanagarindra Institute (IRB No.2563/005) and Institutional Review Board of Sukhothai Hospital (IRB
6
7 No.44/2563). Given no ethics committees are available in the participating community hospitals, participation in this
8
9 study was approved by the hospital directors or representatives. All participants provided written informed consent
10
11 including consent for publication of raw data. (Thai Clinical Trials Registry: TCTR20200426002)
12

13 **Data availability statement** All data relevant to the study are included in the article; the anonymized dataset is
14
15 available upon request by emailing doctorkrit@gmail.com
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Woloshin S, Patel N, Kesselheim A. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. *N Engl J Med* 2020 doi: 10.1056/NEJMp2015897 [published Online First: 2020/06/06]
2. Yong S, Anderson D, Wei W, et al. Connecting clusters of COVID-19: an epidemiological and serological investigation. *Lancet Infect Dis* 2020 doi: 10.1016/s1473-3099(20)30273-5 [published Online First: 2020/04/25]
3. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. *Int J Infect Dis* 2020;98:180-86. doi: 10.1016/j.ijid.2020.06.052 [published Online First: 2020/06/21]
4. Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. *PLoS One* 2020;15(11):e0241536. doi: 10.1371/journal.pone.0241536 [published Online First: 2020/11/04]
5. Chen C, Zhu C, Yan D, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): A systematic review and meta-analysis. *Int J Infect Dis* 2021;104:458-64. doi: 10.1016/j.ijid.2021.01.017 [published Online First: 2021/01/15]
6. Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. *Nat Med* 2020 doi: 10.1038/s41591-020-0949-6 [published Online First: 2020/06/07]
7. Kayı İ, Madran B, Keske Ş, et al. The seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of vaccination: a systematic review and meta-analysis. *Clin Microbiol Infect* 2021 doi: 10.1016/j.cmi.2021.05.036 [published Online First: 2021/06/12]
8. Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 2020;26(6):845-48. doi: 10.1038/s41591-020-0897-1 [published Online First: 2020/05/01]
9. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. *PLoS One* 2020;15(12):e0244126. doi: 10.1371/journal.pone.0244126 [published Online First: 2021/01/01]
10. Walsh K, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *J Infect* 2020;81(3):357-71. doi: 10.1016/j.jinf.2020.06.067 [published Online First: 2020/07/03]
11. Chen M, Qin R, Jiang M, et al. Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review. *Int J Infect Dis* 2021;104:415-22. doi: 10.1016/j.ijid.2021.01.016 [published Online First: 2021/01/16]
12. Steensels D, Oris E, Coninx L, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *Jama* 2020 doi: 10.1001/jama.2020.11160 [published Online First: 2020/06/17]
13. Nopsopon T, Pongpirul K, Chotirosniramit K, et al. Seroprevalence of hospital staff in a province with zero COVID-19 cases. *PLoS One* 2021;16(4):e0238088. doi: 10.1371/journal.pone.0238088 [published Online First: 2021/04/02]
14. Caban-Martinez A, Schaefer-Solle N, Santiago K, et al. Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: a cross-sectional study. LID - oemed-2020-106676 [pii] LID - 10.1136/oemed-2020-106676 [doi]. (1470-7926 (Electronic))
15. Sethuraman N, Jeremiah S, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *Jama* 2020;323(22):2249-51. doi: 10.1001/jama.2020.8259 [published Online First: 2020/05/07]
16. Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. *Cell Mol Immunol* 2020;17(7):773-75. doi: 10.1038/s41423-020-0474-z [published Online First: 2020/05/30]
17. Beeching N, Fletcher T, Beadsworth M. Covid-19: testing times. *Bmj* 2020;369:m1403. doi: 10.1136/bmj.m1403 [published Online First: 2020/04/10]
18. Qin X, Shen J, Dai E, et al. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19. *BMC Immunol* 2021;22(1):14. doi: 10.1186/s12865-021-00404-0 [published Online First: 2021/02/19]
19. Younes N, Al-Sadeq D, Al-Jighefee H, et al. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. *Viruses* 2020;12(6) doi: 10.3390/v12060582 [published Online First: 2020/05/30]
20. Wang B, Wang L, Kong X, et al. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients. *J Med Virol* 2020;92(9):1684-89. doi: 10.1002/jmv.25946 [published Online First: 2020/04/29]
21. Van Praet J, Claeys B, Coene A, et al. Prevention of nosocomial COVID-19: Another challenge of the pandemic. *Infect Control Hosp Epidemiol* 2020;41(11):1355-56. doi: 10.1017/ice.2020.166 [published Online First: 2020/04/24]

- 1
2
3 22. Bhadra A, Mukherjee A, Sarkar K. Impact of population density on Covid-19 infected and mortality rate in
4 India. *Model Earth Syst Environ* 2020:1-7. doi: 10.1007/s40808-020-00984-7 [published Online First:
5 2020/10/20]
6 23. Yin H, Sun T, Yao L, et al. Association between population density and infection rate suggests the importance of
7 social distancing and travel restriction in reducing the COVID-19 pandemic. *Environ Sci Pollut Res Int*
8 2021:1-7. doi: 10.1007/s11356-021-12364-4 [published Online First: 2021/01/15]
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

1
2
3 **Figure legend**
4

5
6 **Figure 1** Unadjusted IgM seroprevalence of hospital staffs and pre-procedural patients in community hospitals
7 across geographical regions of Thailand. Seroprevalence was scaled into color gradient which white region
8 represented the lowest seroprevalence and dark red region represented the highest seroprevalence. Gray region
9 represented region that was not participated in the study.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



COVID-19 Antibody in Thai Community Hospitals

SUPPLEMENTARY FILES

Supplemental Table E1 Geographical distribution of 52 participating community hospitals

	Participating Provinces	Total Provinces	Population of Participating Provinces	Population of All Provinces
Thailand*	35 (46.1%)	76	35,416,545 (58.2%)	60,892,671
Northern	3 (33.3%)	9	2,505,118 (39.4%)	6,350,499
Northeastern	11 (55.0%)	20	15,064,919 (68.4%)	22,014,248
Central*	13 (50.0%)	26	10,053,397 (55.3%)	18,192,361
Southern	6 (42.9%)	14	5,697,112 (60.0%)	9,493,757
Eastern	2 (28.6%)	7	2,095,999 (43.3%)	4,841,806

* Not include Bangkok which has no community hospital.

Data were presented in counts and percentages.

Supplemental Table E2 Number and prevalence of PCR confirmed COVID-19 cases in participating provinces

	PCR Confirmed COVID-19 Cases	Population	PCR Confirmed COVID-19 Prevalence per 100,000 Population
Overall	864	35,416,545	2.44
Northern	47	2,505,118	1.88
Chiang Mai	41	1,779,254	2.30
Mae Hong Son	5	284,138	1.76
Phrae	1	441,726	0.23
Northeastern	85	15,064,919	0.56
Buriram	13	1,595,747	0.81
Chaiyaphum	3	1,137,357	0.26
Kalasin	3	983,418	0.31
Khon Kaen	6	1,802,872	0.33
Maha Sarakham	1	962,665	0.10
Mukdahan	4	353,174	1.13
Nakhon Phanom	2	719,136	0.28
Nakhon	19	2,648,927	0.72
Ratchasima			
Surin	9	1,396,831	0.64
Ubon Ratchathani	15	1,878,146	0.80
Udon Thani	10	1,586,646	0.63
Central	383	10,053,397	3.81
Ayutthaya	4	820,188	0.49
Chainat	0	326,611	0.00
Lopburi	2	755,556	0.26
Nakhon Pathom	22	920,030	2.39
Nonthaburi	158	1,265,387	12.49
Pathum Thani	39	1,163,604	3.35
Phetchaburi	2	485,191	0.41
Phichit	0	536,311	0.00
Samut Prakan	143	1,344,875	10.63
Sukhothai	3	595,072	0.50
Suphanburi	6	846,334	0.71
Tak	3	665,620	0.45
Uthaithani	1	328,618	0.30
Southern	212	5,697,112	3.72
Chumphon	21	511,304	4.11
Krabi	20	476,739	4.20
Nakhon Si	12	1,561,927	0.77
Thammarat			
Songkhla	134	1,435,968	9.33
Surat Thani	18	1,068,010	1.69
Trang	7	643,164	1.09
Eastern	137	2,095,999	6.54
Chanthaburi	3	537,698	0.56
Chonburi	134	1,558,301	8.60

PCR, polymerase chain reaction.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	4	
Methods				
Study design	4	Present key elements of study design early in the paper	4	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	-	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-5	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-5	
Bias	9	Describe any efforts to address potential sources of bias	-	
Study size	10	Explain how the study size was arrived at	4-5	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5-6
		(c) Explain how missing data were addressed	5-6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	4-5
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-7
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6-7
		(b) Indicate number of participants with missing data for each variable of interest	6-7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	-
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-11
		(b) Report category boundaries when continuous variables were categorized	-
		© If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.